<?xml version='1.0' encoding='UTF-8'?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Biomolecules</journal-id><journal-id journal-id-type="iso-abbrev">Biomolecules</journal-id><journal-id journal-id-type="publisher-id">biomolecules</journal-id><journal-title-group><journal-title>Biomolecules</journal-title></journal-title-group><issn pub-type="epub">2218-273X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39199357</article-id><article-id pub-id-type="pmc">11352417</article-id><article-id pub-id-type="doi">10.3390/biom14080969</article-id><article-id pub-id-type="publisher-id">biomolecules-14-00969</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Proteomics and Bioinformatics Identify Drug-Resistant-Related Genes with Prognostic Potential in Cholangiocarcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-0536-0375</contrib-id><name><surname>Kerdkumthong</surname><given-names>Kankamol</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-biomolecules-14-00969" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3696-8390</contrib-id><name><surname>Roytrakul</surname><given-names>Sittiruk</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af2-biomolecules-14-00969" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Songsurin</surname><given-names>Kawinnath</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-biomolecules-14-00969" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Pratummanee</surname><given-names>Kandawasri</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-biomolecules-14-00969" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Runsaeng</surname><given-names>Phanthipha</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-biomolecules-14-00969" ref-type="aff">1</xref><xref rid="af3-biomolecules-14-00969" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3001-0563</contrib-id><name><surname>Obchoei</surname><given-names>Sumalee</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-biomolecules-14-00969" ref-type="aff">1</xref><xref rid="af3-biomolecules-14-00969" ref-type="aff">3</xref><xref rid="c1-biomolecules-14-00969" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Krause</surname><given-names>Frank</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-biomolecules-14-00969"><label>1</label>Department of Biochemistry, Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai District, Songkhla 90110, Thailand; <email>kkerdkumthong@gmail.com</email> (K.K.); <email>kawinnath.ss@gmail.com</email> (K.S.); <email>kandawasri1122@gmail.com</email> (K.P.); <email>phanthipha.r@psu.ac.th</email> (P.R.)</aff><aff id="af2-biomolecules-14-00969"><label>2</label>Functional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Tani 12120, Thailand; <email>sittiruk@biotec.or.th</email></aff><aff id="af3-biomolecules-14-00969"><label>3</label>Center of Excellence for Biochemistry, Faculty of Science, Prince of Songkla University, Hat Yai District, Songkhla 90110, Thailand</aff><author-notes><corresp id="c1-biomolecules-14-00969"><label>*</label>Correspondence: <email>sumalee.o@psu.ac.th</email>; Tel.: +66-74-288-270</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2024</year></pub-date><volume>14</volume><issue>8</issue><elocation-id>969</elocation-id><history><date date-type="received"><day>02</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>05</day><month>8</month><year>2024</year></date></history><permissions><copyright-statement>© 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Drug resistance is a major challenge in the treatment of advanced cholangiocarcinoma (CCA). Understanding the mechanisms of drug resistance can aid in identifying novel prognostic biomarkers and therapeutic targets to improve treatment efficacy. This study established 5-fluorouracil- (5-FU) and gemcitabine-resistant CCA cell lines, KKU-213FR and KKU-213GR, and utilized comparative proteomics to identify differentially expressed proteins in drug-resistant cells compared to parental cells. Additionally, bioinformatics analyses were conducted to explore the biological and clinical significance of key proteins. The drug-resistant phenotypes of KKU-213FR and KKU-213GR cell lines were confirmed. In addition, these cells demonstrated increased migration and invasion abilities. Proteomics analysis identified 81 differentially expressed proteins in drug-resistant cells, primarily related to binding functions, biological regulation, and metabolic processes. Protein–protein interaction analysis revealed a highly interconnected network involving MET, LAMB1, ITGA3, NOTCH2, CDH2, and NDRG1. siRNA-mediated knockdown of these genes in drug-resistant cell lines attenuated cell migration and cell invasion abilities and increased sensitivity to 5-FU and gemcitabine. The mRNA expression of these genes is upregulated in CCA patient samples and is associated with poor prognosis in gastrointestinal cancers. Furthermore, the functions of these proteins are closely related to the epithelial–mesenchymal transition (EMT) pathway. These findings elucidate the potential molecular mechanisms underlying drug resistance and tumor progression in CCA, providing insights into potential therapeutic targets.</p></abstract><kwd-group><kwd>cholangiocarcinoma</kwd><kwd>quantitative proteomics</kwd><kwd>drug resistance</kwd><kwd>5-fluorouracil</kwd><kwd>gemcitabine</kwd><kwd>EMT</kwd></kwd-group><funding-group><award-group><funding-source>National Science, Research and Innovation Fund (NSRF)</funding-source><funding-source>Prince of Songkla University</funding-source><award-id>SCI6701131S</award-id></award-group><award-group><funding-source>Prince of Songkla University—Ph.D. Scholarship</funding-source><award-id>PSU_PHD2561-001</award-id></award-group><award-group><funding-source>Graduate Fellowship (Research Assistant), Faculty of Science, Prince of Songkhla University</funding-source><award-id>1-2565-02-023</award-id></award-group><funding-statement>This research was supported by the National Science, Research and Innovation Fund (NSRF) and Prince of Songkla University (Ref. No. SCI6701131S) to Sumalee Obchoei. Kankamol Kerdkumthong was supported by a Prince of Songkla University—Ph.D. Scholarship (PSU_PHD2561-001). Kandawasri Pratummanee was supported by Graduate Fellowship (Research Assistant), Faculty of Science, Prince of Songkhla University, Contract no. 1-2565-02-023.</funding-statement></funding-group></article-meta></front>
  <body>
    <sec sec-type="intro" id="sec1-biomolecules-14-00969">
      <title>1. Introduction</title>
      <p>Cholangiocarcinoma (CCA), a malignancy affecting the bile ducts, is relatively rare on a global scale. However, its prevalence and mortality rates are notably elevated in specific Asian regions, with the highest occurrences observed in Northeast Thailand [<xref rid="B1-biomolecules-14-00969" ref-type="bibr">1</xref>]. Due to late-stage diagnosis, most CCA cases are ineligible for curative surgical interventions. Consequently, chemotherapy plays a crucial role in the treatment of these late-diagnosed CCA patients [<xref rid="B2-biomolecules-14-00969" ref-type="bibr">2</xref>]. However, the effectiveness of chemotherapy is limited by the acquisition of drug resistance by CCA cells, leading to inevitable tumor recurrence [<xref rid="B3-biomolecules-14-00969" ref-type="bibr">3</xref>]. A deeper understanding of the mechanisms underlying drug resistance holds the potential to enhance the effectiveness of CCA treatment. In the field of cancer research, to identify novel drug-resistant mechanisms or investigate the potency of novel treatments for combating drug resistance, drug-resistant cell lines are often employed [<xref rid="B4-biomolecules-14-00969" ref-type="bibr">4</xref>,<xref rid="B5-biomolecules-14-00969" ref-type="bibr">5</xref>,<xref rid="B6-biomolecules-14-00969" ref-type="bibr">6</xref>,<xref rid="B7-biomolecules-14-00969" ref-type="bibr">7</xref>].</p>
      <p>Proteomics techniques have played a crucial role in advancing our understanding of cancer biology by investigating modifications in signaling pathways within tumor cells. This progress has led to the creation of comprehensive cancer proteome databases, merging molecular and clinical data, and identifying potential therapeutic targets and prognostic markers [<xref rid="B8-biomolecules-14-00969" ref-type="bibr">8</xref>,<xref rid="B9-biomolecules-14-00969" ref-type="bibr">9</xref>,<xref rid="B10-biomolecules-14-00969" ref-type="bibr">10</xref>,<xref rid="B11-biomolecules-14-00969" ref-type="bibr">11</xref>]. Recent examples of such revelations have been observed in various cancers including hepatocellular carcinoma [<xref rid="B12-biomolecules-14-00969" ref-type="bibr">12</xref>], pancreatic cancer [<xref rid="B13-biomolecules-14-00969" ref-type="bibr">13</xref>], glioblastoma [<xref rid="B14-biomolecules-14-00969" ref-type="bibr">14</xref>], and lung adenocarcinoma [<xref rid="B15-biomolecules-14-00969" ref-type="bibr">15</xref>]. However, to our knowledge, proteomic profiling for the elucidation of chemotherapeutic drug-resistant CCA cells has not yet been undertaken.</p>
      <p>In the present study, we established 5-fluorouracil (5-FU) and gemcitabine-resistant cell lines named KKU-213FR and KKU-213GR, respectively, from the KKU-213A parental cell line. Various tumor characteristics such as the drug sensitivity, cell migration, and cell invasion capability of these cells were investigated. Furthermore, quantitative proteomic analysis was conducted to identify differentially expressed proteins in drug-resistant cell lines compared with the parental cell line and to explore the underlying drug-resistant mechanisms. Additionally, various bioinformatic tools were utilized to explore functions and protein–protein interaction networks. The Cancer Genome Atlas Program (TCGA) data were analyzed to investigate the clinical relevance of the key identified proteins.</p>
    </sec>
    <sec id="sec2-biomolecules-14-00969">
      <title>2. Materials and Methods</title>
      <sec id="sec2dot1-biomolecules-14-00969">
        <title>2.1. Cell Culture</title>
        <p>The KKU-213A, formerly known as M213, was established from liver fluke-associated intrahepatic mass-forming CCA tissue with an adenosquamous carcinoma nature from a Thai patient [<xref rid="B16-biomolecules-14-00969" ref-type="bibr">16</xref>,<xref rid="B17-biomolecules-14-00969" ref-type="bibr">17</xref>]. It was obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank in Osaka, Japan. The cell line was cultured under standard conditions in a humidified atmosphere with 5% CO<sub>2</sub> at 37 °C using Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen, Carlsbad, CA, USA), supplemented with 25 mM glucose, 10% fetal bovine serum (FBS, Gibco, Paisley, Scotland), and 1% antibiotic-antimycotic mixture (Gibco, Grand Island, NY, USA).</p>
      </sec>
      <sec id="sec2dot2-biomolecules-14-00969">
        <title>2.2. Establishment of Drug-Resistant CCA Cell Lines</title>
        <p>The chemotherapeutic drugs 5-FU and gemcitabine were purchased from Sigma (Sigma Aldrich, Saint Louis, MO, USA). Drug-resistant cell lines were established using a stepwise concentration incremental method, as previously described [<xref rid="B18-biomolecules-14-00969" ref-type="bibr">18</xref>], with necessary modifications. The parental cell line of KKU-213A cells was initially cultured in DMEM containing the IC<sub>25</sub> concentrations of 5-FU and gemcitabine. After four passages, the drug concentration was increased two-fold. Finally, cell lines growing exponentially in the presence of 7 µM 5-FU and 3 µM gemcitabine were designated as KKU-213FR and KKU-213GR, respectively.</p>
      </sec>
      <sec id="sec2dot3-biomolecules-14-00969">
        <title>2.3. Chemotherapeutic Drug Sensitivity Assay</title>
        <p>The drug-resistant characteristic of the established KKU-213FR and KKU-213GR cell lines was verified through the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. In this process, both drug-resistant cells and their parental counterparts were seeded at a density of 3 × 10<sup>3</sup> cells/well in a 96-well plate and incubated for 24 h. Subsequently, they were exposed to varying concentrations of 5-FU or gemcitabine for 72 h. Afterward, an MTT solution at a concentration of 0.5 mg/mL was introduced into each well and incubated at 37 °C for 2 h. The resulting formazan crystals were dissolved by replacing the medium with 100 µL of dimethyl sulfoxide (DMSO). The absorbance was measured at 540 nm using a microplate reader, enabling the calculation of cell viability percentages for comparison between the drug-resistant and parental cell lines.</p>
      </sec>
      <sec id="sec2dot4-biomolecules-14-00969">
        <title>2.4. Cell Migration and Invasion Assay</title>
        <p>The migration and invasion abilities of cells were evaluated using a modified Boyden chamber technique. In short, 2 × 10<sup>4</sup> cells were placed onto an 8-µm porous polycarbonate membrane in the upper chamber. For the invasion assay, the membrane was pre-coated with 0.5 mg/mL Matrigel (Corning, Bedford, MA, USA). The lower chamber contained a complete medium to encourage cell migration in response to chemoattractants. After 12 h, any non-migrated cells in the upper chamber were removed and the membrane was fixed and stained using a 0.4% sulforhodamine B (SRB) solution. The numbers of migrated and invaded cells were then counted and compared across five randomly chosen low-power fields.</p>
      </sec>
      <sec id="sec2dot5-biomolecules-14-00969">
        <title>2.5. Proteomics Analysis Using LC-MS/MS</title>
        <p>Cell pellets from KKU-213A, KKU-213FR, and KKU-213GR were lysed with 0.5% SDS and centrifuged at 10,000× <italic toggle="yes">g</italic> for 15 min. The resulting supernatant was transferred to a new tube, mixed with two volumes of cold acetone, and incubated overnight at −20 °C. The mixture was thawed and centrifuged again at 10,000× <italic toggle="yes">g</italic> for 15 min. Following the removal of the supernatant, the pellet was dried and stored at −80 °C until needed. Protein concentration of all samples was determined using the Lowry protein assay, with bovine serum albumin (BSA) as the standard protein. To reduce disulfide bonds, a solution of 10 mM dithiothreitol in 10 mM ammonium bicarbonate was added to the protein solution. To prevent reformation of disulfide bonds, the solution was treated with 30 mM iodoacetamide in 10 mM ammonium bicarbonate. Protein samples were digested with sequencing-grade porcine trypsin (at a ratio of 1:20) for 16 h at 37 °C. Subsequently, 100 ng of digested peptides were injected into an Ultimate3000 Nano/Capillary LC System (Thermo Scientific, Oxford, UK) coupled to an HCTUltra LC-MS system (Bruker Daltonics Ltd., Hamburg, Germany) equipped with a nano-captive spray ion source.</p>
        <p>Briefly, the peptide digests were enriched on a μ-Precolumn (300 μm I.D. × 5 mm) C18 PepMap 100 with 5 μm, 100 Å (Thermo Scientific, UK). The peptides were then separated on a 75 μm I.D. × 15 cm column packed with Acclaim PepMap RSLC C18, 2 μm, 100 Å, nanoViper (Thermo Scientific, UK). This column was maintained in a thermostatted column oven at 60 °C. The column was supplied with solvents A and B, which contained 0.1% formic acid in water and 0.1% formic acid in 80% acetonitrile, respectively. Tryptic peptides were eluted from the column using a gradient of 5–55% solvent B at a constant flow rate of 0.30 μL/min for 30 min. Electrospray ionization was performed at 1.6 kV using the CaptiveSpray method with nitrogen as the drying gas at a flow rate of 50 L/h. Mass spectra (MS) and MS/MS spectra were acquired in the positive-ion mode at 2 Hz, covering a range of 150–2200 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>. The collision energy was set at 10 eV based on the <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> value. MS/MS data-dependent acquisition was enabled. The ion trap was configured for positive-ion mode utilizing the manufacturer-specified standard enhanced mode with a scan rate of 8100 <italic toggle="yes">m</italic>/z/s. The scan range spanned from <italic toggle="yes">m/z</italic> 400 to 1500 for MS, averaging five spectra, and accumulated either 100,000 charges [by ion charge control (ICC)] or 200 ms, whichever came first. Collision-induced dissociation (CID) fragmentation was performed on the five most intense ions within the <italic toggle="yes">m/z</italic> range of 200–2800. The threshold for precursor ion selection was set at an absolute intensity of 5000. To prevent redundancy, strict active exclusion was applied: a precursor ion was excluded after two spectra and then reintroduced after a brief 0.3-min interval. The samples were run in three biological replicates of KKU-213A, KKU-213FR, and KKU-213GR, with each replicate undergoing LC-MS analysis in triplicate. A spike of digested BSA was used as an internal standard.</p>
        <p>The DecyderMS 2.0 Differential Analysis software was employed to quantify peptides in individual samples from MS/MS data [<xref rid="B19-biomolecules-14-00969" ref-type="bibr">19</xref>,<xref rid="B20-biomolecules-14-00969" ref-type="bibr">20</xref>]. It provides novel 2D and 3D visualizations of LC-MS data to allow for raw data quality assessment and interactive confirmation of results obtained through automated methods for peptide detection, charge state assignments, and peptide matching across multiple LC-MS experiments. Univariate statistical tools such as Student’s <italic toggle="yes">t</italic>-test and ANOVA are available to identify significantly varying peptides among different groups of samples. Briefly, the raw LC-MS/MS data files were imported into the program, which transformed the information into a virtual peptide image. These images were then processed within the Pepdetect module of DecyderMS. The program initially identifies individual peptides by placing a box around them. Subsequently, ion counts for each peptide are integrated, and the Log<sub>2</sub> of this number is reported. The process is repeated for each replicate sample. This resulting data are then uploaded to the Pepmatch module, where peptides within different virtual images are matched based on <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> and retention time. Notably, because the data was acquired in an ion trap mass spectrometer, tandem MS ensures accurate peptide matching (i.e., MS/MS spectra consistency). Within the Pepmatch module, each virtual image is assigned to a specific group (KKU-213A, KKU-213FR, and KKU-213GR). Group-to-group comparisons are performed. Integrated peptide counts serve as the basis for statistical analyses, assessing the probability that observed changes are not due to chance. False discovery rates are determined from the data.</p>
        <p>MASCOT software, version 2.2 (Matrix Science, London, UK), was used to correlate MS/MS spectra obtained from DecyderMS software to the Homo sapiens protein database (downloaded on 18 August 2021). The search criteria included taxonomy (Homo sapiens), enzyme (trypsin), variable modifications (oxidation of methionine residues), mass values (monoisotopic), protein mass (unrestricted), peptide mass tolerance (1.0 Da), fragment mass tolerance (±0.4 Da), peptide charge states (1+, 2+, and 3+), and a maximum number of missed cleavages [<xref rid="B21-biomolecules-14-00969" ref-type="bibr">21</xref>]. Proteins were identified using one or more peptides with an individual MASCOT score corresponding to <italic toggle="yes">p</italic> &lt; 0.05 and subsequently annotated by UniProtKB/Swiss-Prot entries (<uri xlink:href="http://www.uniprot.org/">http://www.uniprot.org/</uri>; accessed on 18 August 2021).</p>
      </sec>
      <sec id="sec2dot6-biomolecules-14-00969">
        <title>2.6. Identification of Differentially Expressed Proteins</title>
        <p>MetaboAnalyst 6.0 was used for the statistical evaluation of the identified proteins [<xref rid="B22-biomolecules-14-00969" ref-type="bibr">22</xref>]. To illustrate the distinction between various groups of identified proteins, partial least squares-discriminant analysis (PLS-DA) was utilized. Differentially expressed proteins (DEPs) were selected if they showed at least a 3-fold significant difference between drug-resistant cell lines and the parental line, with a false discovery rate (FDR) &lt; 0.05.</p>
        <p>Venn diagrams were generated to show the total number of upregulated and downregulated proteins. To visualize and compare the Log2 expression values of all DEPs, a heatmap was generated using MetaboAnalyst 6.0 [<xref rid="B22-biomolecules-14-00969" ref-type="bibr">22</xref>].</p>
      </sec>
      <sec id="sec2dot7-biomolecules-14-00969">
        <title>2.7. Bioinformatics Analysis</title>
        <p>Protein organization and biological action were conducted on differentially expressed proteins using the protein analysis through evolutionary relationships (Panther software version 18.0; <uri xlink:href="http://pantherdb.org/">http://pantherdb.org/</uri>; accessed on 5 December 2022) protein classification [<xref rid="B23-biomolecules-14-00969" ref-type="bibr">23</xref>]. The categorization included molecular function, biological process, and protein class.</p>
        <p>The gene symbols of all upregulated proteins sharing in both KKU-213FR and KKU-213GR were queried against TCGA data through The University of Alabama at Birmingham Cancer data analysis portal (UALCAN) (<uri xlink:href="http://ualcan.path.uab.edu/index.html">http://ualcan.path.uab.edu/index.html</uri>; accessed on 12 July 2023) [<xref rid="B24-biomolecules-14-00969" ref-type="bibr">24</xref>] to analyze their mRNA expression levels in CCA patients’ tissues. The genes that were upregulated in both drug-resistant cell lines, as indicated by proteomics results, and whose mRNA expression levels were significantly elevated in CCA patients’ tissues according to TCGA data, were filtered and presented in a heatmap. These genes were then subjected to protein–protein interaction prediction and generation using STRING version 11.5 (<uri xlink:href="https://version-11-5.string-db.org">https://version-11-5.string-db.org</uri>; accessed on 30 July 2023) [<xref rid="B25-biomolecules-14-00969" ref-type="bibr">25</xref>]. The following parameters were used: Organism: Homo sapiens; Network type: Full STRING network; Required score: medium confidence (0.4); and FDR stringency: medium (5 percent). The largest protein network, comprising six proteins, was assigned as the ‘focused network’ and further analyzed. The mRNA expression of the six selected genes and the correlations among them were assessed through expression and correlation analysis using the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) platform (<uri xlink:href="http://gepia2.cancer-pku.cn/#correlation">http://gepia2.cancer-pku.cn/#correlation</uri>; accessed on 7 August 2023). The dataset of cholangiocarcinoma (CHOL) and gastrointestinal tract (GI) cancer patients was utilized. The correlation between genes was computed with Pearson correlation coefficients and presented in scatter plots.</p>
      </sec>
      <sec id="sec2dot8-biomolecules-14-00969">
        <title>2.8. Survival Analysis</title>
        <p>The prognostic values of the six genes within the focus network were assessed using TCGA data through the GEPIA2 web portal. Overall survival (OS) and disease-free survival (DFS) were analyzed through Kaplan–Meier survival plots and heatmaps (<uri xlink:href="http://gepia2.cancer-pku.cn/#survival">http://gepia2.cancer-pku.cn/#survival</uri>; accessed on 7 August 2023). Heatmap analysis was employed to compare the contributions of genes to survival in gastrointestinal (GI) tract cancers, with estimates generated using the Mantel–Cox test at a significance level of less than 0.05. Survival analysis was performed based on the expression status of genes in the focused network, and a Kaplan–Meier curve was plotted. The Cox proportional hazards model, including a 95% confidence interval (CI), was used to evaluate the significance of genes in predicting OS and DFS.</p>
      </sec>
      <sec id="sec2dot9-biomolecules-14-00969">
        <title>2.9. RT-qPCR</title>
        <p>The mRNA levels of the six chosen genes were assessed using RT-qPCR, with the beta-actin gene (ACTB) serving as an internal control. Initially, total RNA was isolated from KKU-213A, KKU-213FR, and KKU-213GR cells, as well as from the drug-resistant cells transfected with siRNAs, using the GF-1 total RNA extraction kit (Vivantis, Malaysia), and then converted into cDNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Vilnius, Lithuania). The resulting cDNA was amplified using gene-specific primers (<xref rid="biomolecules-14-00969-t001" ref-type="table">Table 1</xref>) and Maxima SYBR Green/ROX qPCR master Mix (Thermo Scientific, Vilnius, Lithuania), following the manufacturer’s instructions. The qPCR analysis was conducted on an Agilent Technologies Stratagene Mx3005P instrument. The relative mRNA expression levels were normalized using the internal control gene and calculated using the 2<sup>−ΔΔCt</sup> method.</p>
      </sec>
      <sec id="sec2dot10-biomolecules-14-00969">
        <title>2.10. Gene Knockdown Using siRNA</title>
        <p>Specific siRNA sequences targeting MET, LAMB1, ITGA3, NOTCH2, CDH2, and NDRG1 mRNA, as well as a non-targeting negative control siRNA (siNC), were obtained from Gene Universal Inc. (Newark, DE, USA) and are shown in <xref rid="biomolecules-14-00969-t002" ref-type="table">Table 2</xref>. Briefly, for gene knockdown, 2 × 10<sup>5</sup> cells per well were plated in a six-well plate overnight. The next day, the cells were washed and serum-starved in 800 µL per well of Opti-MEM<sup>®</sup> (Gibco, Grand Island, NY, USA) for 1 h. Then, 200 µL of transfection complex containing 100 pmoles siRNA and 2 µL Lipofectamine™ 2000 (Thermo Scientific, Carlsbad, CA, USA) were added to each well. After 6 h of incubation, the medium was changed to complete medium. Twenty-four hours after transfection, the cells were subjected to cell migration, invasion, and drug sensitivity assays, and were harvested for RNA extraction and subsequent RT-qPCR.</p>
      </sec>
      <sec id="sec2dot11-biomolecules-14-00969">
        <title>2.11. Statistical Analysis</title>
        <p>The results are displayed as mean ± standard deviation (SD). The significance of comparisons between groups was evaluated using the two-tailed Student’s <italic toggle="yes">t</italic>-test, with a significance level set at <italic toggle="yes">p</italic> &lt; 0.05. Each experiment was performed with at least three replicates.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3-biomolecules-14-00969">
      <title>3. Results</title>
      <sec id="sec3dot1-biomolecules-14-00969">
        <title>3.1. Drug-Resistant CCA Cell Lines Exhibit Aggressive Behaviors</title>
        <p>We established two chemotherapeutic drug-resistant CCA cell lines, namely KKU-213FR and KKU-213GR, representing the KKU-213A cells resistant to 5-FU and gemcitabine, respectively. These drug-resistant CCA cell lines underwent drug sensitivity assays under various concentrations of 5-FU and gemcitabine. The results confirmed that KKU-213FR cells were resistant to 5-FU, and KKU-213GR cells were resistant to gemcitabine, respectively (<xref rid="biomolecules-14-00969-f001" ref-type="fig">Figure 1</xref>a,b).</p>
        <p>The Boyden chamber migration assays demonstrated that both drug-resistant cell lines exhibited significantly higher migration capabilities than the parental cell line (<xref rid="biomolecules-14-00969-f001" ref-type="fig">Figure 1</xref>c). Similarly, the invasion assay revealed that both KKU-213FR and KKU-213GR had higher invasion rates compared to their parental counterparts (<xref rid="biomolecules-14-00969-f001" ref-type="fig">Figure 1</xref>d).</p>
      </sec>
      <sec id="sec3dot2-biomolecules-14-00969">
        <title>3.2. Comparative Proteomic Analysis of Drug-Resistant CCA Cell Lines</title>
        <p>We employed liquid chromatography with tandem mass spectrometry (LC-MS/MS) to conduct a comparative proteomic analysis of the parental CCA cell line (KKU-213A) and the drug-resistant cell lines (KKU-213FR and KKU-213GR). The proteomics analysis workflow is depicted in <xref rid="biomolecules-14-00969-f002" ref-type="fig">Figure 2</xref>a. In total, 5444, 5894, and 5848 proteins were identified from KKU-213A, KKU-213FR, and KKU-213GR, respectively. The partial least squares-discriminant analysis (PLS-DA) illustrated a good separation of identified proteins among groups (<xref rid="biomolecules-14-00969-f002" ref-type="fig">Figure 2</xref>b). Proteins with expression differences exceeding 3-fold between drug-resistant cell lines and the parental line, with a false discovery rate (FDR) &lt; 0.05, were classified as differentially expressed proteins (DEPs). In KKU-213A vs. KKU-213FR, we identified a total of 279 DEPs, including 137 upregulated and 142 downregulated proteins. In KKU-213A vs. KKU-213GR, we identified 127 DEPs, comprised of 112 upregulated and 15 downregulated proteins. To identify important genes and pathways in these drug-resistant cells, we searched for overlapping DEPs and found 81 DEPs shared by both KKU-213FR and KKU-213GR, with 80 proteins upregulated (<xref rid="biomolecules-14-00969-f002" ref-type="fig">Figure 2</xref>c) and only 1 protein downregulated (<xref rid="biomolecules-14-00969-f002" ref-type="fig">Figure 2</xref>d). The log2 expression values of these proteins in KKU-213A, KKU-213FR, and KKU-213GR were visualized using a heatmap (<xref rid="biomolecules-14-00969-f002" ref-type="fig">Figure 2</xref>e).</p>
      </sec>
      <sec id="sec3dot3-biomolecules-14-00969">
        <title>3.3. Gene Ontology Analysis</title>
        <p>To gain an overall perspective on proteome changes following the development of drug resistance, we subjected the list of DEPs from proteomics data to Gene Ontology (GO) analysis based on the GO database and protein analysis Through Evolutionary Relationships (PANTHER) classification. This allowed us to categorize these proteins based on their molecular function, biological processes, and protein classes (<xref rid="biomolecules-14-00969-f003" ref-type="fig">Figure 3</xref>). As depicted in <xref rid="biomolecules-14-00969-f003" ref-type="fig">Figure 3</xref>a, the largest fraction of the upregulated proteins is associated with the molecular function of binding proteins. Other prominent groups of proteins that exhibited changes include those with catalytic activity, transcriptional regulation, molecular transduction, and transporter activity. Furthermore, the analysis of biological processes revealed that most proteins were involved in cellular processes, followed by metabolic processes, localization, and development processes. Smaller percentages of proteins fell into categories related to responses to stimuli, multicellular organismal processes, signaling, and locomotion (<xref rid="biomolecules-14-00969-f003" ref-type="fig">Figure 3</xref>b). Additionally, these upregulated proteins were mainly classified into categories such as metabolite interconversion enzymes, transcriptional regulators, protein-modifying enzymes, and cytoskeleton proteins (<xref rid="biomolecules-14-00969-f003" ref-type="fig">Figure 3</xref>c).</p>
      </sec>
      <sec id="sec3dot4-biomolecules-14-00969">
        <title>3.4. The mRNA Expression of Upregulated Proteins in CCA Patients’ Tissues</title>
        <p>To investigate whether the 80 upregulated proteins shared in both KKU-213FR and KKU-213GR were also upregulated in CCA patients’ tissues compared to their corresponding normal tissue counterparts, we utilized the UALCAN web portal as an analysis tool based on TCGA data. The results reveal that 25 out of 80 genes (<xref rid="biomolecules-14-00969-f004" ref-type="fig">Figure 4</xref>a) were significantly upregulated in CCA patients’ tissues compared with adjacent normal tissues, as shown in the heatmap in <xref rid="biomolecules-14-00969-f004" ref-type="fig">Figure 4</xref>b. These include TRAP1, CUL3, ARIH1, RPN2, NOTCH2, CDH2, TTLL4, PSMD13, DHX9, WDR74, NDRG1, MET, COMMD3, TERF2, TCP1, DDX19B, DMTF1, EGLN1, LAMB1, SNRPG, TMEM115, ITGA3, GRINA, RCOR3, and TJAP1 (<xref rid="biomolecules-14-00969-f004" ref-type="fig">Figure 4</xref>b).</p>
      </sec>
      <sec id="sec3dot5-biomolecules-14-00969">
        <title>3.5. Identification of Protein–Protein Interaction Networks</title>
        <p>The 25 upregulated proteins were further investigated for protein–protein interactions (PPI) using STRING analysis. The results are represented in <xref rid="biomolecules-14-00969-f004" ref-type="fig">Figure 4</xref>c. The PPI network contains 23 nodes with 14 edges (versus 6 expected edges), a clustering coefficient of 0.514, an enrichment <italic toggle="yes">p</italic>-value of 0.00611, and an average node degree of 1.22, revealing the largest protein network that includes MET, LAMB1, ITGA3, NOTCH2, CDH2, and NDRG1. Smaller networks were also identified, including CUL3, COMMD3, ARIH1, and EGLN1. Additionally, connecting proteins such as DDX19B, DHX9, and SNRPG, along with two more connecting proteins, TCP1 and TRAP1, were identified. Subsequent analyses focused on the largest protein network, designated as the ‘focused network’. The mRNA expression of six genes in the focused network was further analyzed in CCA patients’ samples through the GEPIA2 web portal and verified in drug-resistant CCA cell lines using RT-qPCR. The results, presented as box plots in <xref rid="biomolecules-14-00969-f004" ref-type="fig">Figure 4</xref>d, demonstrate that LAMB1, ITGA3, NOTCH2, and NDRG1 exhibit significantly higher mRNA expression in CCA tissues compared to normal tissues, while the difference was not significant for MET and CDH2. Furthermore, the mRNA levels of all six genes were confirmed to be upregulated in both KKU-213GR and KKU-213FR (<xref rid="biomolecules-14-00969-f004" ref-type="fig">Figure 4</xref>e).</p>
      </sec>
      <sec id="sec3dot6-biomolecules-14-00969">
        <title>3.6. Assessment of the Prognostic Value of Six Selected Genes</title>
        <p>We evaluated the correlation between the overall survival and disease-free survival of CCA patients and the mRNA expression levels of MET, LAMB1, ITGA3, NOTCH2, CDH2, and NDRG1 using TCGA data through the GEPIA2 web portal. No significant correlations were observed, possibly due to the small sample size of CCA patients’ tissues (<xref rid="app1-biomolecules-14-00969" ref-type="app">Figure S1</xref>). We further explored the prognostic value of these six proteins in a pooled dataset of GI tract cancer patients, including cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), and stomach adenocarcinoma (STAD). The results are presented in survival maps (<xref rid="biomolecules-14-00969-f005" ref-type="fig">Figure 5</xref>a,b) and Kaplan–Meier plots (<xref rid="biomolecules-14-00969-f005" ref-type="fig">Figure 5</xref>c,d). High expression levels of LAMB1, ITGA3, NOTCH2, CDH2, and NDRG1 are associated with poor overall survival of GI tract cancer patients (<xref rid="biomolecules-14-00969-f005" ref-type="fig">Figure 5</xref>c). Additionally, elevated expressions of ITGA3, NOTCH2, and CDH2 are indicative of a shorter disease-free survival time (<xref rid="biomolecules-14-00969-f005" ref-type="fig">Figure 5</xref>d).</p>
      </sec>
      <sec id="sec3dot7-biomolecules-14-00969">
        <title>3.7. Correlation among Six Genes in the Focused Network</title>
        <p>To further explore whether the connected proteins found in STRING analysis exhibit correlation in patients’ samples, we investigated the correlation of gene expression between connected proteins in the focused network using the Pearson correlation coefficient through the GEPIA2 platform. Except for CDH2 vs. NDRG1, we identified significant positive correlations between 10 gene pairs in GI tract cancer patients’ data, including MET vs. LAMB1, MET vs. ITGA3, MET vs. NOTCH2, MET vs. NDRG1, LAMB1 vs. ITGA3, LAMB1 vs. NOTCH2, LAMB1 vs. NDRG1, ITGA3 vs. NOTCH2, ITGA3 vs. NDRG1, and NOTCH2 vs. NDRG1. On the other hand, four gene pairs, including MET vs. CDH2, LAMB1 vs. CDH2, ITGA3 vs. CDH2, and CDH2 vs. NDRG1, showed negative correlations (<xref rid="biomolecules-14-00969-f006" ref-type="fig">Figure 6</xref>). Additionally, when analyzing the CHOL dataset alone, we found positive correlations between five gene pairs in CCA patients’ data, including MET vs. LAMB1, MET vs. ITGA3, MET vs. NOTCH2, MET vs. CDH2, and NOTCH2 vs. CDH2 (<xref rid="app1-biomolecules-14-00969" ref-type="app">Figure S2</xref>).</p>
      </sec>
      <sec id="sec3dot8-biomolecules-14-00969">
        <title>3.8. siRNA-Mediated Knockdown of Six Selected Genes Attenuates Cell Migration, Cell Invasion, and Reverses Drug-Resistant Phenotypes</title>
        <p>We further confirmed the significance of the six selected genes using a loss-of-function study with siRNA. Gene knockdown efficiency was confirmed with RT-qPCR, and the results showed that siMET, siLAMB1, siITGA3, siNOTCH2, siCDH2, and siNDRG1 could significantly and effectively suppress the mRNA expression of the respective genes (<xref rid="biomolecules-14-00969-f007" ref-type="fig">Figure 7</xref>a). The drug-resistant CCA cells (KKU-213FR and KKU-213GR) transfected with all six gene-specific siRNAs showed reduced cell migration (<xref rid="biomolecules-14-00969-f007" ref-type="fig">Figure 7</xref>b) and cell invasion (<xref rid="biomolecules-14-00969-f007" ref-type="fig">Figure 7</xref>c) capability when compared to those cells transfected with siNC. Moreover, knockdown of these six genes suppressed the drug-resistant phenotype of these cells (<xref rid="biomolecules-14-00969-f007" ref-type="fig">Figure 7</xref>d).</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4-biomolecules-14-00969">
      <title>4. Discussion</title>
      <p>Despite recent advancements in surgical techniques, chemotherapy, and the development of targeted therapies at the molecular level, the primary cause of cancer-related deaths is still the progressive growth of metastases that show resistance to existing treatments [<xref rid="B26-biomolecules-14-00969" ref-type="bibr">26</xref>]. Although chemotherapy is a commonly employed approach for managing advanced CCA patients, even with combinations of drugs, the median survival rate remains below one year [<xref rid="B27-biomolecules-14-00969" ref-type="bibr">27</xref>]. This challenge arises from the intricate mechanisms of chemoresistance, which typically aid cancer cells in evading the lethal effects of anticancer drugs. Thus, gaining a deeper comprehension of the molecular foundations of drug resistance is crucial for unraveling the complex mechanisms and indicators associated with drug-resistant characteristics.</p>
      <p>Previous research has successfully developed cell lines that are resistant to commonly used chemotherapeutic drugs 5-FU and gemcitabine in various cancer types, and these cell lines have become invaluable tools for elucidating drug resistance mechanisms and identifying potential therapeutic targets in cancer research. For instance, 5-FU resistance has been achieved in hepatocellular carcinoma cells (HLF-cell line) [<xref rid="B28-biomolecules-14-00969" ref-type="bibr">28</xref>], colorectal cancer cells (HCT-8 and H630) [<xref rid="B29-biomolecules-14-00969" ref-type="bibr">29</xref>,<xref rid="B30-biomolecules-14-00969" ref-type="bibr">30</xref>], breast cancer cells (T47D) [<xref rid="B30-biomolecules-14-00969" ref-type="bibr">30</xref>], triple-negative breast cancer cells (MDA-MB-231) [<xref rid="B31-biomolecules-14-00969" ref-type="bibr">31</xref>], and gastric cancer cells (SNU638) [<xref rid="B32-biomolecules-14-00969" ref-type="bibr">32</xref>]. In pancreatic cancer, gemcitabine-resistant cell lines have been established, such as SW1990 [<xref rid="B33-biomolecules-14-00969" ref-type="bibr">33</xref>], PaCa-2 [<xref rid="B34-biomolecules-14-00969" ref-type="bibr">34</xref>], PANC [<xref rid="B35-biomolecules-14-00969" ref-type="bibr">35</xref>], and in pancreatic ductal carcinoma cell lines [<xref rid="B36-biomolecules-14-00969" ref-type="bibr">36</xref>]. Additionally, gemcitabine-resistant cell lines have also been developed in CCA, specifically KKU-M139 and KKU-M214 cell lines [<xref rid="B18-biomolecules-14-00969" ref-type="bibr">18</xref>]. In this research, we successfully established 5-FU- and gemcitabine-resistant CCA cell lines KKU-213FR and KKU-213GR (<xref rid="biomolecules-14-00969-f001" ref-type="fig">Figure 1</xref>a,b).</p>
      <p>The intricate process of drug resistance in cancer cells linked to metastasis-related differentiation signaling involves dynamic changes in both cancer and stromal cells [<xref rid="B37-biomolecules-14-00969" ref-type="bibr">37</xref>]. Metastasis encompasses a decrease in tumor cell adhesion receptor expression, promoting heightened cell motility, while invasion entails the disassembly of the extracellular matrix (ECM) [<xref rid="B38-biomolecules-14-00969" ref-type="bibr">38</xref>]. Patients with chemotherapeutic resistance in CCA often undergo advanced cancer recurrence with metastasis [<xref rid="B39-biomolecules-14-00969" ref-type="bibr">39</xref>]. Subsequently, we explored the metastatic potential of 5-FU- and gemcitabine-resistant CCA cell lines. Further assessment through the Boyden chamber assay demonstrated a higher number of migrated and invaded cells, affirming the heightened metastatic potential of the established drug-resistant cell line (<xref rid="biomolecules-14-00969-f001" ref-type="fig">Figure 1</xref>c,d).</p>
      <p>To investigate alterations in cellular mechanisms related to drug resistance, we identified changes in the proteome profiles. A total of 80 proteins were upregulated in both KKU-213FR and KKU-213GR when compared to the parental cell line. These proteins underwent classification using GO analysis, categorizing them based on their molecular function, biological process, and protein class. The upregulated proteins were primarily classified under the molecular function category of ‘binding’ (GO: 0005488). Previous studies have highlighted the significant roles played by various binding proteins in cancer progression and the development of drug resistance. These proteins function in diverse ways such as transmitting signals through signaling molecules [<xref rid="B40-biomolecules-14-00969" ref-type="bibr">40</xref>,<xref rid="B41-biomolecules-14-00969" ref-type="bibr">41</xref>], altering the number or mutation of receptors [<xref rid="B42-biomolecules-14-00969" ref-type="bibr">42</xref>,<xref rid="B43-biomolecules-14-00969" ref-type="bibr">43</xref>,<xref rid="B44-biomolecules-14-00969" ref-type="bibr">44</xref>], and releasing cytokines [<xref rid="B45-biomolecules-14-00969" ref-type="bibr">45</xref>,<xref rid="B46-biomolecules-14-00969" ref-type="bibr">46</xref>].</p>
      <p>Drug resistance mechanisms involve alterations in various cellular processes such as increased cell replication [<xref rid="B47-biomolecules-14-00969" ref-type="bibr">47</xref>,<xref rid="B48-biomolecules-14-00969" ref-type="bibr">48</xref>], transcriptional activation of drug-resistant genes or oncogenes [<xref rid="B49-biomolecules-14-00969" ref-type="bibr">49</xref>,<xref rid="B50-biomolecules-14-00969" ref-type="bibr">50</xref>], and DNA repair in response to exposure to chemotherapeutic drugs to prevent cell death [<xref rid="B51-biomolecules-14-00969" ref-type="bibr">51</xref>,<xref rid="B52-biomolecules-14-00969" ref-type="bibr">52</xref>,<xref rid="B53-biomolecules-14-00969" ref-type="bibr">53</xref>].</p>
      <p>The second largest group of proteins was categorized under biological regulation and metabolic processes. In response to chemotherapeutic agents, cancer cells that possess the ability to evade cell death caused by the drugs can alter their biological processes to sustain growth or proliferation [<xref rid="B54-biomolecules-14-00969" ref-type="bibr">54</xref>,<xref rid="B55-biomolecules-14-00969" ref-type="bibr">55</xref>], migrate to other parts of the body by reducing cell adhesion [<xref rid="B56-biomolecules-14-00969" ref-type="bibr">56</xref>,<xref rid="B57-biomolecules-14-00969" ref-type="bibr">57</xref>], and secrete enzymes or signals to modulate the extracellular matrix [<xref rid="B58-biomolecules-14-00969" ref-type="bibr">58</xref>,<xref rid="B59-biomolecules-14-00969" ref-type="bibr">59</xref>].</p>
      <p>When categorized via protein class, the majority of upregulated proteins were classified as metabolite interconversion enzymes. Metabolic reprogramming of cancer cells can hinder immune responses and create obstacles to cancer treatment. Cancer cells must balance increasing metabolic demands associated with uncontrolled cell division and metastasis, which often render them resistant to current therapies. Several studies have discovered abnormalities in metabolism in chemotherapy-resistant cancers [<xref rid="B60-biomolecules-14-00969" ref-type="bibr">60</xref>,<xref rid="B61-biomolecules-14-00969" ref-type="bibr">61</xref>,<xref rid="B62-biomolecules-14-00969" ref-type="bibr">62</xref>].</p>
      <p>We further compared upregulated proteins from the proteomic data to their mRNA expression in patients’ tissues from the TCGA database through the UALCAN platform [<xref rid="B24-biomolecules-14-00969" ref-type="bibr">24</xref>]. Among the 80 upregulated proteins identified in drug-resistant cell lines based on proteomics analysis, only 25 were found to be upregulated in cholangiocarcinoma (CCA) tissues compared to normal tissues when analyzed using TCGA data through the UALCAN web portal. This discrepancy may be attributed to the absence of comparative gene expression data between chemosensitive and chemoresistant CCA patient samples within the CHOL dataset. The 25 overlapping genes may play a crucial role in both drug resistance and carcinogenesis in CCA, whereas the remaining 56 non-overlapping genes may solely contribute to the development of drug resistance. Future research involving the analysis of these 80 upregulated genes in drug-sensitive and drug-resistant clinical samples will further elucidate their roles in drug-resistant CCA. When subjected to STRING analysis, we identified a highly interconnected network comprising six proteins: MET, LAMB1, ITGA3, NOTCH2, CDH2, and NDRG1. It is notable that a medium confidence level (0.4) was used as a parameter in the STRING analysis. If high confidence (0.7) was used, the protein network would remain largely similar, except for the exclusion of NOTCH2 and NDRG1. To avoid excluding significant genes, the medium confidence value was utilized. Nearly all of the proteins in this network, except for MET, were associated with the poor prognosis in GI tract cancer patients (<xref rid="biomolecules-14-00969-f005" ref-type="fig">Figure 5</xref>). Although statistical significance was not found when analyzing CCA data alone, it was likely due to the small sample size. Furthermore, the mRNA expression in patients’ samples of genes in the focused network was positively correlated with each other (<xref rid="biomolecules-14-00969-f006" ref-type="fig">Figure 6</xref>). Interestingly, the silencing of these six genes reduces cell motility rates and attenuates the chemotherapeutic-resistant phenotype of both KKU-213FR and KKU-213GR (<xref rid="biomolecules-14-00969-f007" ref-type="fig">Figure 7</xref>).</p>
      <p>Several past investigations have demonstrated the oncogenic functions of these proteins in different cancer types. The mesenchymal epithelial transition factor (MET), alternatively termed hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase. When it interacts with its ligand, hepatocyte growth factor triggers various cellular signaling pathways related to proliferation, motility, migration, and invasion [<xref rid="B63-biomolecules-14-00969" ref-type="bibr">63</xref>,<xref rid="B64-biomolecules-14-00969" ref-type="bibr">64</xref>].</p>
      <p>Laminin beta-1 (LAMB1), a type of extracellular matrix (ECM) glycoprotein, is present in most tissues and is responsible for initiating cell assembly. This assembly is crucial for the invasion and spread of cancer cells [<xref rid="B65-biomolecules-14-00969" ref-type="bibr">65</xref>]. Studies have shown that LAMB1 is significantly expressed in multiple invasive cancers [<xref rid="B66-biomolecules-14-00969" ref-type="bibr">66</xref>] and plays a significant role in cancer progression, as observed in gastric cancer [<xref rid="B67-biomolecules-14-00969" ref-type="bibr">67</xref>,<xref rid="B68-biomolecules-14-00969" ref-type="bibr">68</xref>], and lung adenocarcinoma [<xref rid="B66-biomolecules-14-00969" ref-type="bibr">66</xref>].</p>
      <p>Integrin alpha-3 (ITGA3) is a cell membrane-bound integrin protein receptor that plays a role within the ECM. Its function involves serving as a cell surface adhesion molecule and engaging with various ECM-receptor proteins such as integrin beta-1 (ITGB1), members of the laminin family, and fibronectin 1 [<xref rid="B69-biomolecules-14-00969" ref-type="bibr">69</xref>].</p>
      <p>Neurogenic locus notch homolog protein 2 (NOTCH2) is a product of the <italic toggle="yes">NOTCH2</italic> gene. It plays dual roles in cell interactions and serves as a highly conserved signal transduction system once its ligand binds. Overexpression of NOTCH2 has been identified in multiple cancer types including breast cancer [<xref rid="B70-biomolecules-14-00969" ref-type="bibr">70</xref>], lung squamous cell carcinoma [<xref rid="B71-biomolecules-14-00969" ref-type="bibr">71</xref>], leukemia [<xref rid="B72-biomolecules-14-00969" ref-type="bibr">72</xref>], ovarian cancer [<xref rid="B73-biomolecules-14-00969" ref-type="bibr">73</xref>], and colorectal cancer [<xref rid="B74-biomolecules-14-00969" ref-type="bibr">74</xref>]. The activation of NOTCH2 is linked to various mechanisms in tumor development such as regulating the properties of tumor-initiating cells, controlling signaling pathways like MYC [<xref rid="B75-biomolecules-14-00969" ref-type="bibr">75</xref>] or P53 [<xref rid="B76-biomolecules-14-00969" ref-type="bibr">76</xref>,<xref rid="B77-biomolecules-14-00969" ref-type="bibr">77</xref>], promoting angiogenesis [<xref rid="B78-biomolecules-14-00969" ref-type="bibr">78</xref>], regulating tumor invasion [<xref rid="B79-biomolecules-14-00969" ref-type="bibr">79</xref>,<xref rid="B80-biomolecules-14-00969" ref-type="bibr">80</xref>], and managing the cell cycle [<xref rid="B81-biomolecules-14-00969" ref-type="bibr">81</xref>,<xref rid="B82-biomolecules-14-00969" ref-type="bibr">82</xref>].</p>
      <p>CDH2, also known as neuronal cadherin (N-cadherin), is a marker of epithelial-to-mesenchymal transition (EMT). CDH2 is referred to as a ‘mesenchymal cadherin’, which replaces epithelial cadherin (E-cadherin) during the epithelial-to-mesenchymal transition known as the cadherin ‘switch’ [<xref rid="B83-biomolecules-14-00969" ref-type="bibr">83</xref>,<xref rid="B84-biomolecules-14-00969" ref-type="bibr">84</xref>]. CDH2’s functions are associated with fibroblast growth factor receptors (FGFRs). This interaction leads to continuous FGFR signaling and the progression of carcinoma [<xref rid="B85-biomolecules-14-00969" ref-type="bibr">85</xref>]. Additionally, CDH2 enhances the activity of nuclear β-catenin-mediated drug resistance in myeloma [<xref rid="B86-biomolecules-14-00969" ref-type="bibr">86</xref>]. The roles of CDH2 have been demonstrated in several cancers such as increasing invasiveness in melanoma cancer [<xref rid="B87-biomolecules-14-00969" ref-type="bibr">87</xref>] and esophageal squamous cell carcinomas [<xref rid="B88-biomolecules-14-00969" ref-type="bibr">88</xref>].</p>
      <p>N-myc downregulated gene-1 (NDRG1) is known to have diverse roles, functioning both as a suppressor of metastasis and as an indicator of poor prognosis, while also contributing to disease progression across various cancer types [<xref rid="B89-biomolecules-14-00969" ref-type="bibr">89</xref>]. Although NDRG1 is primarily recognized for its anti-oncogenic and anti-metastatic functions [<xref rid="B90-biomolecules-14-00969" ref-type="bibr">90</xref>,<xref rid="B91-biomolecules-14-00969" ref-type="bibr">91</xref>,<xref rid="B92-biomolecules-14-00969" ref-type="bibr">92</xref>], studies have revealed its pro-oncogenic role in certain cancers like gastric cancer and hepatocellular carcinoma [<xref rid="B93-biomolecules-14-00969" ref-type="bibr">93</xref>]. In clinical samples of esophageal cancer, elevated levels of NDRG1 were associated with the malignant advancement of the disease [<xref rid="B94-biomolecules-14-00969" ref-type="bibr">94</xref>]. This study proposed that NDRG1 influences the Wnt signaling pathway and the accumulation of β-catenin through the mediation of Wnt-associated genes, thereby promoting metastasis [<xref rid="B83-biomolecules-14-00969" ref-type="bibr">83</xref>]. Indeed, reducing NDRG1 levels in gastric cancer cells led to increased E-cadherin expression and decreased vimentin expression, indicating a link between high NDRG1 levels and the metastatic potential of gastric cancer cells [<xref rid="B95-biomolecules-14-00969" ref-type="bibr">95</xref>]. Overall, the role of NDRG1 in either promoting or suppressing tumor progression is highly dependent on the specific type of tumor cell and its degree of differentiation.</p>
      <p>Taken together, MET, LAMB1, ITGA3, NOTCH2, CDH2, and NDRG1 were upregulated in drug-resistant CCA cell lines and in CCA patients’ tissues. These genes not only contribute to acquired drug resistance but also play a crucial role in the progression of CCA cells. They share a common role in activating tumor metastasis through EMT pathways. <xref rid="biomolecules-14-00969-f008" ref-type="fig">Figure 8</xref> provides a schematic picture illustrating the predicted functional role of these proteins in the development of drug resistance and progression of CCA.</p>
    </sec>
    <sec sec-type="conclusions" id="sec5-biomolecules-14-00969">
      <title>5. Conclusions</title>
      <p>Despite advancements in cancer therapies, metastasis-driven drug resistance poses a formidable challenge leading to high mortality rates. Our study successfully established 5-FU- and gemcitabine-resistant CCA cell lines KKU-213FR and KKU-213GR, which exhibited increased cell motility and invasion. Through the integration of proteomics analysis and bioinformatics, we identified 25 genes that were upregulated in drug-resistant cell lines as well as in patients’ tissues. Further investigation revealed a network of six highly interconnected genes (MET, LAMB1, ITGA3, NOTCH2, CDH2, and NDRG1) whose expressions are correlated with each other. Furthermore, the mRNA expression of these genes is associated with a poor prognosis in GI tract cancer patients, emphasizing their potential as prognostic markers and possibly therapeutic targets.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p>
      </fn>
    </fn-group>
    <app-group>
      <app id="app1-biomolecules-14-00969">
        <title>Supplementary Materials</title>
        <p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/biom14080969/s1">https://www.mdpi.com/article/10.3390/biom14080969/s1</uri>, Figure S1. Survival analyses of six selected genes in CCA patients; Figure S2. The correlation analysis of six focused genes in CCA cancers.</p>
        <supplementary-material id="biomolecules-14-00969-s001" position="float" content-type="local-data">
          <media xlink:href="biomolecules-14-00969-s001.zip"/>
        </supplementary-material>
      </app>
    </app-group>
    <notes>
      <title>Author Contributions</title>
      <p>Conceptualization, K.K. and S.O.; data curation, K.K., S.R., P.R. and S.O.; formal analysis, K.K. and S.R.; funding acquisition, S.O., investigation, K.K., S.R., K.S. and K.P.; methodology, K.K. and S.O.; resources, S.R., P.R. and S.O.; validation, S.R., P.R. and S.O.; visualization, K.K., K.S. and K.P.; writing–original draft and editing, K.K. and S.O.; writing–review &amp; editing, S.O. All authors have read and agreed to the published version of the manuscript.</p>
    </notes>
    <notes>
      <title>Institutional Review Board Statement</title>
      <p>Not applicable.</p>
    </notes>
    <notes>
      <title>Informed Consent Statement</title>
      <p>Not applicable.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data Availability Statement</title>
      <p>All data generated or analyzed during this study are included in this published article and its <xref rid="app1-biomolecules-14-00969" ref-type="app">Supplementary Information Files</xref>. The MS/MS raw data and analysis have been deposited in the ProteomeXchange Consortium via the jPOST partner repository with the data set identifier JPST002506 and PXD049309 (<uri xlink:href="https://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD049309">https://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD049309</uri>, accessed on 29 July 2024).</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflicts of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-biomolecules-14-00969">
        <label>1.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banales</surname><given-names>J.M.</given-names></name>
<name><surname>Marin</surname><given-names>J.J.</given-names></name>
<name><surname>Lamarca</surname><given-names>A.</given-names></name>
<name><surname>Rodrigues</surname><given-names>P.M.</given-names></name>
<name><surname>Khan</surname><given-names>S.A.</given-names></name>
<name><surname>Roberts</surname><given-names>L.R.</given-names></name>
<name><surname>Cardinale</surname><given-names>V.</given-names></name>
<name><surname>Carpino</surname><given-names>G.</given-names></name>
<name><surname>Andersen</surname><given-names>J.B.</given-names></name>
<name><surname>Braconi</surname><given-names>C.</given-names></name>
</person-group><article-title>Cholangiocarcinoma 2020: The next horizon in mechanisms and management</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2020</year><volume>17</volume><fpage>557</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1038/s41575-020-0310-z</pub-id><pub-id pub-id-type="pmid">32606456</pub-id>
</element-citation>
      </ref>
      <ref id="B2-biomolecules-14-00969">
        <label>2.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tawarungruang</surname><given-names>C.</given-names></name>
<name><surname>Khuntikeo</surname><given-names>N.</given-names></name>
<name><surname>Chamadol</surname><given-names>N.</given-names></name>
<name><surname>Laopaiboon</surname><given-names>V.</given-names></name>
<name><surname>Thuanman</surname><given-names>J.</given-names></name>
<name><surname>Thinkhamrop</surname><given-names>K.</given-names></name>
<name><surname>Kelly</surname><given-names>M.</given-names></name>
<name><surname>Thinkhamrop</surname><given-names>B.</given-names></name>
</person-group><article-title>Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification</article-title><source>BMC Cancer</source><year>2021</year><volume>21</volume><elocation-id>497</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-021-08247-z</pub-id><pub-id pub-id-type="pmid">33941120</pub-id>
</element-citation>
      </ref>
      <ref id="B3-biomolecules-14-00969">
        <label>3.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marin</surname><given-names>J.J.</given-names></name>
<name><surname>Lozano</surname><given-names>E.</given-names></name>
<name><surname>Herraez</surname><given-names>E.</given-names></name>
<name><surname>Asensio</surname><given-names>M.</given-names></name>
<name><surname>Di Giacomo</surname><given-names>S.</given-names></name>
<name><surname>Romero</surname><given-names>M.R.</given-names></name>
<name><surname>Briz</surname><given-names>O.</given-names></name>
<name><surname>Serrano</surname><given-names>M.A.</given-names></name>
<name><surname>Efferth</surname><given-names>T.</given-names></name>
<name><surname>Macias</surname><given-names>R.I.</given-names></name>
</person-group><article-title>Chemoresistance and chemosensitization in cholangiocarcinoma</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><year>2018</year><volume>1864</volume><fpage>1444</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2017.06.005</pub-id><pub-id pub-id-type="pmid">28600147</pub-id>
</element-citation>
      </ref>
      <ref id="B4-biomolecules-14-00969">
        <label>4.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamangar</surname><given-names>F.</given-names></name>
<name><surname>Dores</surname><given-names>G.M.</given-names></name>
<name><surname>Anderson</surname><given-names>W.F.</given-names></name>
</person-group><article-title>Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world</article-title><source>J. Clin. Oncol.</source><year>2006</year><volume>24</volume><fpage>2137</fpage><lpage>2150</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.05.2308</pub-id><pub-id pub-id-type="pmid">16682732</pub-id>
</element-citation>
      </ref>
      <ref id="B5-biomolecules-14-00969">
        <label>5.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Govindan</surname><given-names>S.V.</given-names></name>
<name><surname>Kulsum</surname><given-names>S.</given-names></name>
<name><surname>Pandian</surname><given-names>R.S.</given-names></name>
<name><surname>Das</surname><given-names>D.</given-names></name>
<name><surname>Seshadri</surname><given-names>M.</given-names></name>
<name><surname>Hicks</surname><given-names>W.</given-names></name>
<name><surname>Kuriakose</surname><given-names>M.A.</given-names></name>
<name><surname>Suresh</surname><given-names>A.</given-names></name>
</person-group><article-title>Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines</article-title><source>Mol. Med. Rep.</source><year>2015</year><volume>12</volume><fpage>3025</fpage><lpage>3032</lpage><pub-id pub-id-type="doi">10.3892/mmr.2015.3768</pub-id><pub-id pub-id-type="pmid">25962396</pub-id>
</element-citation>
      </ref>
      <ref id="B6-biomolecules-14-00969">
        <label>6.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>G.</given-names></name>
<name><surname>Huang</surname><given-names>K.-C.</given-names></name>
<name><surname>Cardenas</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Matei</surname><given-names>D.</given-names></name>
<name><surname>Cheng</surname><given-names>J.-X.</given-names></name>
</person-group><article-title>Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>4554</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32101-w</pub-id><pub-id pub-id-type="pmid">35931676</pub-id>
</element-citation>
      </ref>
      <ref id="B7-biomolecules-14-00969">
        <label>7.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zuo</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>M.</given-names></name>
<name><surname>Guo</surname><given-names>L.</given-names></name>
<name><surname>Liao</surname><given-names>W.</given-names></name>
</person-group><article-title>Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><elocation-id>11634</elocation-id><pub-id pub-id-type="doi">10.1038/srep11634</pub-id><pub-id pub-id-type="pmid">26108989</pub-id>
</element-citation>
      </ref>
      <ref id="B8-biomolecules-14-00969">
        <label>8.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Posadas</surname><given-names>E.</given-names></name>
<name><surname>Simpkins</surname><given-names>F.</given-names></name>
<name><surname>Liotta</surname><given-names>L.</given-names></name>
<name><surname>MacDonald</surname><given-names>C.</given-names></name>
<name><surname>Kohn</surname><given-names>E.</given-names></name>
</person-group><article-title>Proteomic analysis for the early detection and rational treatment of cancer—Realistic hope?</article-title><source>Ann. Oncol.</source><year>2005</year><volume>16</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi004</pub-id><pub-id pub-id-type="pmid">15598930</pub-id>
</element-citation>
      </ref>
      <ref id="B9-biomolecules-14-00969">
        <label>9.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nanjundan</surname><given-names>M.</given-names></name>
<name><surname>Byers</surname><given-names>L.A.</given-names></name>
<name><surname>Carey</surname><given-names>M.S.</given-names></name>
<name><surname>Siwak</surname><given-names>D.R.</given-names></name>
<name><surname>Raso</surname><given-names>M.G.</given-names></name>
<name><surname>Diao</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Coombes</surname><given-names>K.R.</given-names></name>
<name><surname>Roth</surname><given-names>J.A.</given-names></name>
<name><surname>Mills</surname><given-names>G.B.</given-names></name>
</person-group><article-title>Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence</article-title><source>J. Thorac. Oncol.</source><year>2010</year><volume>5</volume><fpage>1894</fpage><lpage>1904</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e3181f2a266</pub-id><pub-id pub-id-type="pmid">21124077</pub-id>
</element-citation>
      </ref>
      <ref id="B10-biomolecules-14-00969">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Sahukar Shruthi</surname><given-names>B.</given-names></name>
<name><surname>Vinodhkumar</surname><given-names>P.</given-names></name>
<name><surname>Amani</surname><given-names>S.</given-names></name>
</person-group>
          <article-title>Proteomics: A new perspective for cancer</article-title>
          <source>Adv. Biomed. Res.</source>
          <year>2016</year>
          <volume>2016</volume>
          <elocation-id>67</elocation-id>
          <pub-id pub-id-type="doi">10.4103/2277-9175.180636</pub-id>
        </element-citation>
      </ref>
      <ref id="B11-biomolecules-14-00969">
        <label>11.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>L.</given-names></name>
<name><surname>Ni</surname><given-names>J.</given-names></name>
<name><surname>Beretov</surname><given-names>J.</given-names></name>
<name><surname>Wasinger</surname><given-names>V.C.</given-names></name>
<name><surname>Hao</surname><given-names>J.</given-names></name>
<name><surname>Bucci</surname><given-names>J.</given-names></name>
<name><surname>Malouf</surname><given-names>D.</given-names></name>
<name><surname>Gillatt</surname><given-names>D.</given-names></name>
<name><surname>Graham</surname><given-names>P.H.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>41834</elocation-id><pub-id pub-id-type="doi">10.1038/srep41834</pub-id><pub-id pub-id-type="pmid">28225015</pub-id>
</element-citation>
      </ref>
      <ref id="B12-biomolecules-14-00969">
        <label>12.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>Q.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Dong</surname><given-names>L.</given-names></name>
<name><surname>Shi</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Song</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Dong</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
</person-group><article-title>Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma</article-title><source>Cell</source><year>2019</year><volume>179</volume><fpage>561</fpage><lpage>577.e22</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.08.052</pub-id><pub-id pub-id-type="pmid">31585088</pub-id>
</element-citation>
      </ref>
      <ref id="B13-biomolecules-14-00969">
        <label>13.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brandi</surname><given-names>J.</given-names></name>
<name><surname>Dando</surname><given-names>I.</given-names></name>
<name><surname>Dalla Pozza</surname><given-names>E.</given-names></name>
<name><surname>Biondani</surname><given-names>G.</given-names></name>
<name><surname>Jenkins</surname><given-names>R.</given-names></name>
<name><surname>Elliott</surname><given-names>V.</given-names></name>
<name><surname>Park</surname><given-names>K.</given-names></name>
<name><surname>Fanelli</surname><given-names>G.</given-names></name>
<name><surname>Zolla</surname><given-names>L.</given-names></name>
<name><surname>Costello</surname><given-names>E.</given-names></name>
</person-group><article-title>Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways</article-title><source>J. Proteomics</source><year>2017</year><volume>150</volume><fpage>310</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2016.10.002</pub-id><pub-id pub-id-type="pmid">27746256</pub-id>
</element-citation>
      </ref>
      <ref id="B14-biomolecules-14-00969">
        <label>14.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>M.K.</given-names></name>
<name><surname>Polisetty</surname><given-names>R.V.</given-names></name>
<name><surname>Sharma</surname><given-names>R.</given-names></name>
<name><surname>Ganesh</surname><given-names>R.A.</given-names></name>
<name><surname>Gowda</surname><given-names>H.</given-names></name>
<name><surname>Purohit</surname><given-names>A.K.</given-names></name>
<name><surname>Ankathi</surname><given-names>P.</given-names></name>
<name><surname>Prasad</surname><given-names>K.</given-names></name>
<name><surname>Mariswamappa</surname><given-names>K.</given-names></name>
<name><surname>Lakshmikantha</surname><given-names>A.</given-names></name>
</person-group><article-title>Altered transcriptional regulatory proteins in glioblastoma and YBX1 as a potential regulator of tumor invasion</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>10986</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-47360-9</pub-id><pub-id pub-id-type="pmid">31358880</pub-id>
</element-citation>
      </ref>
      <ref id="B15-biomolecules-14-00969">
        <label>15.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lignitto</surname><given-names>L.</given-names></name>
<name><surname>LeBoeuf</surname><given-names>S.E.</given-names></name>
<name><surname>Homer</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Askenazi</surname><given-names>M.</given-names></name>
<name><surname>Karakousi</surname><given-names>T.R.</given-names></name>
<name><surname>Pass</surname><given-names>H.I.</given-names></name>
<name><surname>Bhutkar</surname><given-names>A.J.</given-names></name>
<name><surname>Tsirigos</surname><given-names>A.</given-names></name>
<name><surname>Ueberheide</surname><given-names>B.</given-names></name>
</person-group><article-title>Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1</article-title><source>Cell</source><year>2019</year><volume>178</volume><fpage>316</fpage><lpage>329.e18</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.06.003</pub-id><pub-id pub-id-type="pmid">31257023</pub-id>
</element-citation>
      </ref>
      <ref id="B16-biomolecules-14-00969">
        <label>16.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sripa</surname><given-names>B.</given-names></name>
<name><surname>Leungwattanawanit</surname><given-names>S.</given-names></name>
<name><surname>Nitta</surname><given-names>T.</given-names></name>
<name><surname>Wongkham</surname><given-names>C.</given-names></name>
<name><surname>Bhudhisawasdi</surname><given-names>V.</given-names></name>
<name><surname>Puapairoj</surname><given-names>A.</given-names></name>
<name><surname>Sripa</surname><given-names>C.</given-names></name>
<name><surname>Miwa</surname><given-names>M.</given-names></name>
</person-group><article-title>Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)</article-title><source>World J. Gastroenterol.</source><year>2005</year><volume>11</volume><fpage>3392</fpage><pub-id pub-id-type="doi">10.3748/wjg.v11.i22.3392</pub-id><pub-id pub-id-type="pmid">15948244</pub-id>
</element-citation>
      </ref>
      <ref id="B17-biomolecules-14-00969">
        <label>17.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sripa</surname><given-names>B.</given-names></name>
<name><surname>Seubwai</surname><given-names>W.</given-names></name>
<name><surname>Vaeteewoottacharn</surname><given-names>K.</given-names></name>
<name><surname>Sawanyawisuth</surname><given-names>K.</given-names></name>
<name><surname>Silsirivanit</surname><given-names>A.</given-names></name>
<name><surname>Kaewkong</surname><given-names>W.</given-names></name>
<name><surname>Muisuk</surname><given-names>K.</given-names></name>
<name><surname>Dana</surname><given-names>P.</given-names></name>
<name><surname>Phoomak</surname><given-names>C.</given-names></name>
<name><surname>Lert-Itthiporn</surname><given-names>W.</given-names></name>
</person-group><article-title>Functional and genetic characterization of three cell lines derived from a single tumor of an <italic toggle="yes">Opisthorchis viverrini-</italic> associated cholangiocarcinoma patient</article-title><source>Human Cell</source><year>2020</year><volume>33</volume><fpage>695</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1007/s13577-020-00334-w</pub-id><pub-id pub-id-type="pmid">32207095</pub-id>
</element-citation>
      </ref>
      <ref id="B18-biomolecules-14-00969">
        <label>18.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wattanawongdon</surname><given-names>W.</given-names></name>
<name><surname>Hahnvajanawong</surname><given-names>C.</given-names></name>
<name><surname>Namwat</surname><given-names>N.</given-names></name>
<name><surname>Kanchanawat</surname><given-names>S.</given-names></name>
<name><surname>Boonmars</surname><given-names>T.</given-names></name>
<name><surname>Jearanaikoon</surname><given-names>P.</given-names></name>
<name><surname>Leelayuwat</surname><given-names>C.</given-names></name>
<name><surname>Techasen</surname><given-names>A.</given-names></name>
<name><surname>Seubwai</surname><given-names>W.</given-names></name>
</person-group><article-title>Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness</article-title><source>Int. J. Oncol.</source><year>2015</year><volume>47</volume><fpage>398</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.3892/ijo.2015.3019</pub-id><pub-id pub-id-type="pmid">25998688</pub-id>
</element-citation>
      </ref>
      <ref id="B19-biomolecules-14-00969">
        <label>19.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johansson</surname><given-names>C.</given-names></name>
<name><surname>Samskog</surname><given-names>J.</given-names></name>
<name><surname>Sundström</surname><given-names>L.</given-names></name>
<name><surname>Wadensten</surname><given-names>H.</given-names></name>
<name><surname>Björkesten</surname><given-names>L.</given-names></name>
<name><surname>Flensburg</surname><given-names>J.</given-names></name>
</person-group><article-title>Differential expression analysis of Escherichia coli proteins using a novel software for relative quantitation of LC-MS/MS data</article-title><source>Proteomics</source><year>2006</year><volume>6</volume><fpage>4475</fpage><lpage>4485</lpage><pub-id pub-id-type="doi">10.1002/pmic.200500921</pub-id><pub-id pub-id-type="pmid">16858737</pub-id>
</element-citation>
      </ref>
      <ref id="B20-biomolecules-14-00969">
        <label>20.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thorsell</surname><given-names>A.</given-names></name>
<name><surname>Portelius</surname><given-names>E.</given-names></name>
<name><surname>Blennow</surname><given-names>K.</given-names></name>
<name><surname>Westman-Brinkmalm</surname><given-names>A.</given-names></name>
</person-group><article-title>Evaluation of sample fractionation using micro-scale liquid-phase isoelectric focusing on mass spectrometric identification and quantitation of proteins in a SILAC experiment</article-title><source>Rapid Commun. Mass Spectrom.</source><year>2007</year><volume>21</volume><fpage>771</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1002/rcm.2898</pub-id><pub-id pub-id-type="pmid">17279600</pub-id>
</element-citation>
      </ref>
      <ref id="B21-biomolecules-14-00969">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Perkins</surname><given-names>D.N.</given-names></name>
<name><surname>Pappin</surname><given-names>D.J.</given-names></name>
<name><surname>Creasy</surname><given-names>D.M.</given-names></name>
<name><surname>Cottrell</surname><given-names>J.S.</given-names></name>
</person-group>
          <article-title>Probability-based protein identification by searching sequence databases using mass spectrometry data</article-title>
          <source>ELECTROPHORESIS Int. J.</source>
          <year>1999</year>
          <volume>20</volume>
          <fpage>3551</fpage>
          <lpage>3567</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1522-2683(19991201)20:18&lt;3551::AID-ELPS3551&gt;3.0.CO;2-2</pub-id>
        </element-citation>
      </ref>
      <ref id="B22-biomolecules-14-00969">
        <label>22.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pang</surname><given-names>Z.</given-names></name>
<name><surname>Zhou</surname><given-names>G.</given-names></name>
<name><surname>Ewald</surname><given-names>J.</given-names></name>
<name><surname>Chang</surname><given-names>L.</given-names></name>
<name><surname>Hacariz</surname><given-names>O.</given-names></name>
<name><surname>Basu</surname><given-names>N.</given-names></name>
<name><surname>Xia</surname><given-names>J.</given-names></name>
</person-group><article-title>Using MetaboAnalyst 5.0 for LC–HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data</article-title><source>Nat. Protoc.</source><year>2022</year><volume>17</volume><fpage>1735</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1038/s41596-022-00710-w</pub-id><pub-id pub-id-type="pmid">35715522</pub-id>
</element-citation>
      </ref>
      <ref id="B23-biomolecules-14-00969">
        <label>23.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mi</surname><given-names>H.</given-names></name>
<name><surname>Muruganujan</surname><given-names>A.</given-names></name>
<name><surname>Ebert</surname><given-names>D.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Thomas</surname><given-names>P.D.</given-names></name>
</person-group><article-title>PANTHER version 14: More genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>D419</fpage><lpage>D426</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1038</pub-id><pub-id pub-id-type="pmid">30407594</pub-id>
</element-citation>
      </ref>
      <ref id="B24-biomolecules-14-00969">
        <label>24.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chandrashekar</surname><given-names>D.S.</given-names></name>
<name><surname>Karthikeyan</surname><given-names>S.K.</given-names></name>
<name><surname>Korla</surname><given-names>P.K.</given-names></name>
<name><surname>Patel</surname><given-names>H.</given-names></name>
<name><surname>Shovon</surname><given-names>A.R.</given-names></name>
<name><surname>Athar</surname><given-names>M.</given-names></name>
<name><surname>Netto</surname><given-names>G.J.</given-names></name>
<name><surname>Qin</surname><given-names>Z.S.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Manne</surname><given-names>U.</given-names></name>
</person-group><article-title>UALCAN: An update to the integrated cancer data analysis platform</article-title><source>Neoplasia</source><year>2022</year><volume>25</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2022.01.001</pub-id><pub-id pub-id-type="pmid">35078134</pub-id>
</element-citation>
      </ref>
      <ref id="B25-biomolecules-14-00969">
        <label>25.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szklarczyk</surname><given-names>D.</given-names></name>
<name><surname>Gable</surname><given-names>A.L.</given-names></name>
<name><surname>Nastou</surname><given-names>K.C.</given-names></name>
<name><surname>Lyon</surname><given-names>D.</given-names></name>
<name><surname>Kirsch</surname><given-names>R.</given-names></name>
<name><surname>Pyysalo</surname><given-names>S.</given-names></name>
<name><surname>Doncheva</surname><given-names>N.T.</given-names></name>
<name><surname>Legeay</surname><given-names>M.</given-names></name>
<name><surname>Fang</surname><given-names>T.</given-names></name>
<name><surname>Bork</surname><given-names>P.</given-names></name>
</person-group><article-title>The STRING database in 2021: Customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>D605</fpage><lpage>D612</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1074</pub-id><pub-id pub-id-type="pmid">33237311</pub-id>
</element-citation>
      </ref>
      <ref id="B26-biomolecules-14-00969">
        <label>26.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Housman</surname><given-names>G.</given-names></name>
<name><surname>Byler</surname><given-names>S.</given-names></name>
<name><surname>Heerboth</surname><given-names>S.</given-names></name>
<name><surname>Lapinska</surname><given-names>K.</given-names></name>
<name><surname>Longacre</surname><given-names>M.</given-names></name>
<name><surname>Snyder</surname><given-names>N.</given-names></name>
<name><surname>Sarkar</surname><given-names>S.</given-names></name>
</person-group><article-title>Drug resistance in cancer: An overview</article-title><source>Cancers</source><year>2014</year><volume>6</volume><fpage>1769</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.3390/cancers6031769</pub-id><pub-id pub-id-type="pmid">25198391</pub-id>
</element-citation>
      </ref>
      <ref id="B27-biomolecules-14-00969">
        <label>27.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thongprasert</surname><given-names>S.</given-names></name>
</person-group><article-title>The role of chemotherapy in cholangiocarcinoma</article-title><source>Ann. Oncol.</source><year>2005</year><volume>16</volume><fpage>ii93</fpage><lpage>ii96</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi712</pub-id><pub-id pub-id-type="pmid">15958484</pub-id>
</element-citation>
      </ref>
      <ref id="B28-biomolecules-14-00969">
        <label>28.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uchibori</surname><given-names>K.</given-names></name>
<name><surname>Kasamatsu</surname><given-names>A.</given-names></name>
<name><surname>Sunaga</surname><given-names>M.</given-names></name>
<name><surname>Yokota</surname><given-names>S.</given-names></name>
<name><surname>Sakurada</surname><given-names>T.</given-names></name>
<name><surname>Kobayashi</surname><given-names>E.</given-names></name>
<name><surname>Yoshikawa</surname><given-names>M.</given-names></name>
<name><surname>Uzawa</surname><given-names>K.</given-names></name>
<name><surname>Ueda</surname><given-names>S.</given-names></name>
<name><surname>Tanzawa</surname><given-names>H.</given-names></name>
</person-group><article-title>Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines</article-title><source>Int. J. Oncol.</source><year>2012</year><volume>40</volume><fpage>1005</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.3892/ijo.2011.1300</pub-id><pub-id pub-id-type="pmid">22179686</pub-id>
</element-citation>
      </ref>
      <ref id="B29-biomolecules-14-00969">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>He</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>T.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Mao</surname><given-names>H.</given-names></name>
<name><surname>SekharKathera</surname><given-names>C.</given-names></name>
<name><surname>Janardhan</surname><given-names>A.</given-names></name>
<name><surname>Edick</surname><given-names>A.M.</given-names></name>
</person-group>
          <article-title>Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells</article-title>
          <source>Exp. Mol. Med.</source>
          <year>2018</year>
          <volume>50</volume>
          <fpage>1</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1038/s12276-018-0128-8</pub-id>
        </element-citation>
      </ref>
      <ref id="B30-biomolecules-14-00969">
        <label>30.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Cassidy</surname><given-names>J.</given-names></name>
<name><surname>O’Brien</surname><given-names>V.</given-names></name>
<name><surname>Ryan</surname><given-names>K.M.</given-names></name>
<name><surname>Collie-Duguid</surname><given-names>E.</given-names></name>
</person-group><article-title>Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>8167</fpage><lpage>8176</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0970</pub-id><pub-id pub-id-type="pmid">15548681</pub-id>
</element-citation>
      </ref>
      <ref id="B31-biomolecules-14-00969">
        <label>31.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takahashi</surname><given-names>K.</given-names></name>
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<name><surname>Inagaki</surname><given-names>A.</given-names></name>
<name><surname>Wanibuchi</surname><given-names>H.</given-names></name>
<name><surname>Izumi</surname><given-names>Y.</given-names></name>
<name><surname>Miura</surname><given-names>K.</given-names></name>
<name><surname>Nagayama</surname><given-names>K.</given-names></name>
<name><surname>Shiota</surname><given-names>M.</given-names></name>
<name><surname>Iwao</surname><given-names>H.</given-names></name>
</person-group><article-title>Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line</article-title><source>Int. J. Oncol.</source><year>2013</year><volume>43</volume><fpage>1985</fpage><lpage>1991</lpage><pub-id pub-id-type="doi">10.3892/ijo.2013.2135</pub-id><pub-id pub-id-type="pmid">24126575</pub-id>
</element-citation>
      </ref>
      <ref id="B32-biomolecules-14-00969">
        <label>32.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chung</surname><given-names>Y.M.</given-names></name>
<name><surname>Park</surname><given-names>S.-H.</given-names></name>
<name><surname>Park</surname><given-names>J.K.</given-names></name>
<name><surname>Kim</surname><given-names>Y.-T.</given-names></name>
<name><surname>Kang</surname><given-names>Y.-K.</given-names></name>
<name><surname>Do Yoo</surname><given-names>Y.</given-names></name>
</person-group><article-title>Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells</article-title><source>Cancer Lett.</source><year>2000</year><volume>159</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(00)00535-8</pub-id><pub-id pub-id-type="pmid">10974411</pub-id>
</element-citation>
      </ref>
      <ref id="B33-biomolecules-14-00969">
        <label>33.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Ding</surname><given-names>F.</given-names></name>
<name><surname>Gao</surname><given-names>M.</given-names></name>
<name><surname>Jia</surname><given-names>Y.F.</given-names></name>
<name><surname>Ren</surname><given-names>L.</given-names></name>
</person-group><article-title>Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine</article-title><source>Oncol. Lett.</source><year>2019</year><volume>18</volume><fpage>3065</fpage><lpage>3071</lpage><pub-id pub-id-type="doi">10.3892/ol.2019.10627</pub-id><pub-id pub-id-type="pmid">31452783</pub-id>
</element-citation>
      </ref>
      <ref id="B34-biomolecules-14-00969">
        <label>34.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Togawa</surname><given-names>A.</given-names></name>
<name><surname>Ito</surname><given-names>H.</given-names></name>
<name><surname>Kimura</surname><given-names>F.</given-names></name>
<name><surname>Shimizu</surname><given-names>H.</given-names></name>
<name><surname>Ohtsuka</surname><given-names>M.</given-names></name>
<name><surname>Shimamura</surname><given-names>F.</given-names></name>
<name><surname>Yoshidome</surname><given-names>H.</given-names></name>
<name><surname>Katoh</surname><given-names>A.</given-names></name>
<name><surname>Miyazaki</surname><given-names>M.</given-names></name>
</person-group><article-title>Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-a on the resistant cell line</article-title><source>Pancreas</source><year>2003</year><volume>27</volume><fpage>220</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1097/00006676-200310000-00004</pub-id><pub-id pub-id-type="pmid">14508125</pub-id>
</element-citation>
      </ref>
      <ref id="B35-biomolecules-14-00969">
        <label>35.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Fu</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>A.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
</person-group><article-title>Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression</article-title><source>Oncol. Rep.</source><year>2015</year><volume>33</volume><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.3892/or.2014.3599</pub-id><pub-id pub-id-type="pmid">25394408</pub-id>
</element-citation>
      </ref>
      <ref id="B36-biomolecules-14-00969">
        <label>36.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fujiwara-Tani</surname><given-names>R.</given-names></name>
<name><surname>Sasaki</surname><given-names>T.</given-names></name>
<name><surname>Takagi</surname><given-names>T.</given-names></name>
<name><surname>Mori</surname><given-names>S.</given-names></name>
<name><surname>Kishi</surname><given-names>S.</given-names></name>
<name><surname>Nishiguchi</surname><given-names>Y.</given-names></name>
<name><surname>Ohmori</surname><given-names>H.</given-names></name>
<name><surname>Fujii</surname><given-names>K.</given-names></name>
<name><surname>Kuniyasu</surname><given-names>H.</given-names></name>
</person-group><article-title>Gemcitabine resistance in pancreatic ductal carcinoma cell lines stems from reprogramming of energy metabolism</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>7824</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23147824</pub-id><pub-id pub-id-type="pmid">35887170</pub-id>
</element-citation>
      </ref>
      <ref id="B37-biomolecules-14-00969">
        <label>37.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mansoori</surname><given-names>B.</given-names></name>
<name><surname>Mohammadi</surname><given-names>A.</given-names></name>
<name><surname>Davudian</surname><given-names>S.</given-names></name>
<name><surname>Shirjang</surname><given-names>S.</given-names></name>
<name><surname>Baradaran</surname><given-names>B.</given-names></name>
</person-group><article-title>The different mechanisms of cancer drug resistance: A brief review</article-title><source>Adv. Pharm. Bull.</source><year>2017</year><volume>7</volume><fpage>339</fpage><pub-id pub-id-type="doi">10.15171/apb.2017.041</pub-id><pub-id pub-id-type="pmid">29071215</pub-id>
</element-citation>
      </ref>
      <ref id="B38-biomolecules-14-00969">
        <label>38.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>S.U.</given-names></name>
<name><surname>Fatima</surname><given-names>K.</given-names></name>
<name><surname>Aisha</surname><given-names>S.</given-names></name>
<name><surname>Malik</surname><given-names>F.</given-names></name>
</person-group><article-title>Unveiling the mechanisms and challenges of cancer drug resistance</article-title><source>Cell Commun. Signal</source><year>2024</year><volume>22</volume><fpage>109</fpage><pub-id pub-id-type="doi">10.1186/s12964-023-01302-1</pub-id><pub-id pub-id-type="pmid">38347575</pub-id>
</element-citation>
      </ref>
      <ref id="B39-biomolecules-14-00969">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Rao</surname><given-names>L.</given-names></name>
<name><surname>Ma</surname><given-names>N.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
<name><surname>Qu</surname><given-names>B.</given-names></name>
</person-group>
          <article-title>Correlation between adjuvant chemotherapy regimen, recurrence pattern and prognosis of cholangiocarcinoma after radical surgery</article-title>
          <source>Front. Oncol.</source>
          <year>2022</year>
          <volume>12</volume>
          <elocation-id>324</elocation-id>
          <pub-id pub-id-type="doi">10.3389/fonc.2022.695228</pub-id>
        </element-citation>
      </ref>
      <ref id="B40-biomolecules-14-00969">
        <label>40.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahl</surname><given-names>P.B.</given-names></name>
<name><surname>Lin</surname><given-names>C.Y.</given-names></name>
<name><surname>Seila</surname><given-names>A.C.</given-names></name>
<name><surname>Flynn</surname><given-names>R.A.</given-names></name>
<name><surname>McCuine</surname><given-names>S.</given-names></name>
<name><surname>Burge</surname><given-names>C.B.</given-names></name>
<name><surname>Sharp</surname><given-names>P.A.</given-names></name>
<name><surname>Young</surname><given-names>R.A.</given-names></name>
</person-group><article-title>c-Myc regulates transcriptional pause release</article-title><source>Cell</source><year>2010</year><volume>141</volume><fpage>432</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.03.030</pub-id><pub-id pub-id-type="pmid">20434984</pub-id>
</element-citation>
      </ref>
      <ref id="B41-biomolecules-14-00969">
        <label>41.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cichowski</surname><given-names>K.</given-names></name>
<name><surname>Jacks</surname><given-names>T.</given-names></name>
</person-group><article-title>NF1 tumor suppressor gene function: Narrowing the GAP</article-title><source>Cell</source><year>2001</year><volume>104</volume><fpage>593</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00245-8</pub-id><pub-id pub-id-type="pmid">11239415</pub-id>
</element-citation>
      </ref>
      <ref id="B42-biomolecules-14-00969">
        <label>42.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krook</surname><given-names>M.A.</given-names></name>
<name><surname>Reeser</surname><given-names>J.W.</given-names></name>
<name><surname>Ernst</surname><given-names>G.</given-names></name>
<name><surname>Barker</surname><given-names>H.</given-names></name>
<name><surname>Wilberding</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Chen</surname><given-names>H.-Z.</given-names></name>
<name><surname>Roychowdhury</surname><given-names>S.</given-names></name>
</person-group><article-title>Fibroblast growth factor receptors in cancer: Genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance</article-title><source>Br. J. Cancer</source><year>2021</year><volume>124</volume><fpage>880</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-01157-0</pub-id><pub-id pub-id-type="pmid">33268819</pub-id>
</element-citation>
      </ref>
      <ref id="B43-biomolecules-14-00969">
        <label>43.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>S.V.</given-names></name>
<name><surname>Bell</surname><given-names>D.W.</given-names></name>
<name><surname>Settleman</surname><given-names>J.</given-names></name>
<name><surname>Haber</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Epidermal growth factor receptor mutations in lung cancer</article-title><source>Nat. Rev. Cancer</source><year>2007</year><volume>7</volume><fpage>169</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1038/nrc2088</pub-id><pub-id pub-id-type="pmid">17318210</pub-id>
</element-citation>
      </ref>
      <ref id="B44-biomolecules-14-00969">
        <label>44.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morova</surname><given-names>T.</given-names></name>
<name><surname>McNeill</surname><given-names>D.R.</given-names></name>
<name><surname>Lallous</surname><given-names>N.</given-names></name>
<name><surname>Gönen</surname><given-names>M.</given-names></name>
<name><surname>Dalal</surname><given-names>K.</given-names></name>
<name><surname>Wilson</surname><given-names>D.M.</given-names><suffix>III</suffix></name>
<name><surname>Gürsoy</surname><given-names>A.</given-names></name>
<name><surname>Keskin</surname><given-names>Ö.</given-names></name>
<name><surname>Lack</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Androgen receptor-binding sites are highly mutated in prostate cancer</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>832</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14644-y</pub-id><pub-id pub-id-type="pmid">32047165</pub-id>
</element-citation>
      </ref>
      <ref id="B45-biomolecules-14-00969">
        <label>45.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>M.C.</given-names></name>
<name><surname>Pallone</surname><given-names>F.</given-names></name>
</person-group><article-title>Cytokines: From gut inflammation to colorectal cancer</article-title><source>Curr. Drug Targets</source><year>2008</year><volume>9</volume><fpage>375</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.2174/138945008784221206</pub-id><pub-id pub-id-type="pmid">18473765</pub-id>
</element-citation>
      </ref>
      <ref id="B46-biomolecules-14-00969">
        <label>46.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matanić</surname><given-names>D.</given-names></name>
<name><surname>Beg-Zec</surname><given-names>Z.</given-names></name>
<name><surname>Stojanović</surname><given-names>D.</given-names></name>
<name><surname>Matakorić</surname><given-names>N.</given-names></name>
<name><surname>Flego</surname><given-names>V.</given-names></name>
<name><surname>Milevoj-Ribić</surname><given-names>F.</given-names></name>
</person-group><article-title>Cytokines in patients with lung cancer</article-title><source>Scand. J. Immunol.</source><year>2003</year><volume>57</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3083.2003.01205.x</pub-id><pub-id pub-id-type="pmid">12588664</pub-id>
</element-citation>
      </ref>
      <ref id="B47-biomolecules-14-00969">
        <label>47.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikolaou</surname><given-names>M.</given-names></name>
<name><surname>Pavlopoulou</surname><given-names>A.</given-names></name>
<name><surname>Georgakilas</surname><given-names>A.G.</given-names></name>
<name><surname>Kyrodimos</surname><given-names>E.</given-names></name>
</person-group><article-title>The challenge of drug resistance in cancer treatment: A current overview</article-title><source>Clin. Exp. Metastasis</source><year>2018</year><volume>35</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1007/s10585-018-9903-0</pub-id><pub-id pub-id-type="pmid">29799080</pub-id>
</element-citation>
      </ref>
      <ref id="B48-biomolecules-14-00969">
        <label>48.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holm</surname><given-names>P.S.</given-names></name>
<name><surname>Lage</surname><given-names>H.</given-names></name>
<name><surname>Bergmann</surname><given-names>S.</given-names></name>
<name><surname>Jürchott</surname><given-names>K.</given-names></name>
<name><surname>Glockzin</surname><given-names>G.</given-names></name>
<name><surname>Bernshausen</surname><given-names>A.</given-names></name>
<name><surname>Mantwill</surname><given-names>K.</given-names></name>
<name><surname>Ladhoff</surname><given-names>A.</given-names></name>
<name><surname>Wichert</surname><given-names>A.</given-names></name>
<name><surname>Mymryk</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: Impact for cancer gene therapy</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>322</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-0482-2</pub-id><pub-id pub-id-type="pmid">14729641</pub-id>
</element-citation>
      </ref>
      <ref id="B49-biomolecules-14-00969">
        <label>49.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cole</surname><given-names>S.</given-names></name>
<name><surname>Bhardwaj</surname><given-names>G.</given-names></name>
<name><surname>Gerlach</surname><given-names>J.</given-names></name>
<name><surname>Mackie</surname><given-names>J.</given-names></name>
<name><surname>Grant</surname><given-names>C.</given-names></name>
<name><surname>Almquist</surname><given-names>K.</given-names></name>
<name><surname>Stewart</surname><given-names>A.</given-names></name>
<name><surname>Kurz</surname><given-names>E.</given-names></name>
<name><surname>Duncan</surname><given-names>A.</given-names></name>
<name><surname>Deeley</surname><given-names>R.G.</given-names></name>
</person-group><article-title>Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line</article-title><source>Science</source><year>1992</year><volume>258</volume><fpage>1650</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1126/science.1360704</pub-id><pub-id pub-id-type="pmid">1360704</pub-id>
</element-citation>
      </ref>
      <ref id="B50-biomolecules-14-00969">
        <label>50.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morrow</surname><given-names>C.</given-names></name>
<name><surname>Cowan</surname><given-names>K.</given-names></name>
</person-group><article-title>Glutathione S-transferases and drug resistance</article-title><source>Cancer Cells</source><year>1990</year><volume>2</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/0300-9629(91)90616-K</pub-id><pub-id pub-id-type="pmid">2201336</pub-id>
</element-citation>
      </ref>
      <ref id="B51-biomolecules-14-00969">
        <label>51.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Shah</surname><given-names>N.A.</given-names></name>
<name><surname>Joiner</surname><given-names>A.M.</given-names></name>
<name><surname>Roberts</surname><given-names>K.H.</given-names></name>
<name><surname>Canman</surname><given-names>C.E.</given-names></name>
</person-group><article-title>DNA polymerase ζ is a major determinant of resistance to platinum-based chemotherapeutic agents</article-title><source>Mol. Pharmacol.</source><year>2012</year><volume>81</volume><fpage>778</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1124/mol.111.076828</pub-id><pub-id pub-id-type="pmid">22387291</pub-id>
</element-citation>
      </ref>
      <ref id="B52-biomolecules-14-00969">
        <label>52.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zamble</surname><given-names>D.B.</given-names></name>
<name><surname>Lippard</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Cisplatin and DNA repair in cancer chemotherapy</article-title><source>Trends Biochem. Sci.</source><year>1995</year><volume>20</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(00)89095-7</pub-id><pub-id pub-id-type="pmid">8533159</pub-id>
</element-citation>
      </ref>
      <ref id="B53-biomolecules-14-00969">
        <label>53.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pang</surname><given-names>B.</given-names></name>
<name><surname>Qiao</surname><given-names>X.</given-names></name>
<name><surname>Janssen</surname><given-names>L.</given-names></name>
<name><surname>Velds</surname><given-names>A.</given-names></name>
<name><surname>Groothuis</surname><given-names>T.</given-names></name>
<name><surname>Kerkhoven</surname><given-names>R.</given-names></name>
<name><surname>Nieuwland</surname><given-names>M.</given-names></name>
<name><surname>Ovaa</surname><given-names>H.</given-names></name>
<name><surname>Rottenberg</surname><given-names>S.</given-names></name>
<name><surname>Van Tellingen</surname><given-names>O.</given-names></name>
</person-group><article-title>Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin</article-title><source>Nat. Commun.</source><year>2013</year><volume>4</volume><fpage>1908</fpage><pub-id pub-id-type="doi">10.1038/ncomms2921</pub-id><pub-id pub-id-type="pmid">23715267</pub-id>
</element-citation>
      </ref>
      <ref id="B54-biomolecules-14-00969">
        <label>54.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamphorst</surname><given-names>A.O.</given-names></name>
<name><surname>Pillai</surname><given-names>R.N.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Nasti</surname><given-names>T.H.</given-names></name>
<name><surname>Akondy</surname><given-names>R.S.</given-names></name>
<name><surname>Wieland</surname><given-names>A.</given-names></name>
<name><surname>Sica</surname><given-names>G.L.</given-names></name>
<name><surname>Yu</surname><given-names>K.</given-names></name>
<name><surname>Koenig</surname><given-names>L.</given-names></name>
<name><surname>Patel</surname><given-names>N.T.</given-names></name>
</person-group><article-title>Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>4993</fpage><lpage>4998</lpage><pub-id pub-id-type="doi">10.1073/pnas.1705327114</pub-id><pub-id pub-id-type="pmid">28446615</pub-id>
</element-citation>
      </ref>
      <ref id="B55-biomolecules-14-00969">
        <label>55.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roninson</surname><given-names>I.B.</given-names></name>
<name><surname>Broude</surname><given-names>E.V.</given-names></name>
<name><surname>Chang</surname><given-names>B.-D.</given-names></name>
</person-group><article-title>If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells</article-title><source>Drug Resist. Updat.</source><year>2001</year><volume>4</volume><fpage>303</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1054/drup.2001.0213</pub-id><pub-id pub-id-type="pmid">11991684</pub-id>
</element-citation>
      </ref>
      <ref id="B56-biomolecules-14-00969">
        <label>56.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>S.</given-names></name>
<name><surname>Golubovskaya</surname><given-names>V.M.</given-names></name>
<name><surname>Conroy</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Cance</surname><given-names>W.G.</given-names></name>
</person-group><article-title>FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>7945</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.2381</pub-id><pub-id pub-id-type="pmid">25277206</pub-id>
</element-citation>
      </ref>
      <ref id="B57-biomolecules-14-00969">
        <label>57.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Kong</surname><given-names>D.</given-names></name>
<name><surname>Banerjee</surname><given-names>S.</given-names></name>
<name><surname>Ahmad</surname><given-names>A.</given-names></name>
<name><surname>Azmi</surname><given-names>A.S.</given-names></name>
<name><surname>Ali</surname><given-names>S.</given-names></name>
<name><surname>Abbruzzese</surname><given-names>J.L.</given-names></name>
<name><surname>Gallick</surname><given-names>G.E.</given-names></name>
<name><surname>Sarkar</surname><given-names>F.H.</given-names></name>
</person-group><article-title>Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway</article-title><source>Cancer Res.</source><year>2009</year><volume>69</volume><fpage>2400</fpage><lpage>2407</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4312</pub-id><pub-id pub-id-type="pmid">19276344</pub-id>
</element-citation>
      </ref>
      <ref id="B58-biomolecules-14-00969">
        <label>58.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erdogan</surname><given-names>B.</given-names></name>
<name><surname>Webb</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis</article-title><source>Biochem. Soc. Trans.</source><year>2017</year><volume>45</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1042/BST20160387</pub-id><pub-id pub-id-type="pmid">28202677</pub-id>
</element-citation>
      </ref>
      <ref id="B59-biomolecules-14-00969">
        <label>59.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sprenger</surname><given-names>C.C.</given-names></name>
<name><surname>Plymate</surname><given-names>S.R.</given-names></name>
<name><surname>Reed</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression</article-title><source>Int. J. Cancer</source><year>2010</year><volume>127</volume><fpage>2739</fpage><lpage>2748</lpage><pub-id pub-id-type="doi">10.1002/ijc.25615</pub-id><pub-id pub-id-type="pmid">21351253</pub-id>
</element-citation>
      </ref>
      <ref id="B60-biomolecules-14-00969">
        <label>60.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>W.</given-names></name>
<name><surname>Liang</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Yao</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>Q.</given-names></name>
<name><surname>Liao</surname><given-names>W.</given-names></name>
</person-group><article-title>MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer</article-title><source>Oncogene</source><year>2019</year><volume>38</volume><fpage>4637</fpage><lpage>4654</lpage><pub-id pub-id-type="doi">10.1038/s41388-019-0747-0</pub-id><pub-id pub-id-type="pmid">30742067</pub-id>
</element-citation>
      </ref>
      <ref id="B61-biomolecules-14-00969">
        <label>61.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iwamoto</surname><given-names>H.</given-names></name>
<name><surname>Abe</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Cui</surname><given-names>D.</given-names></name>
<name><surname>Seki</surname><given-names>T.</given-names></name>
<name><surname>Nakamura</surname><given-names>M.</given-names></name>
<name><surname>Hosaka</surname><given-names>K.</given-names></name>
<name><surname>Lim</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>X.</given-names></name>
</person-group><article-title>Cancer lipid metabolism confers antiangiogenic drug resistance</article-title><source>Cell Metab.</source><year>2018</year><volume>28</volume><fpage>104</fpage><lpage>117.e5</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.05.005</pub-id><pub-id pub-id-type="pmid">29861385</pub-id>
</element-citation>
      </ref>
      <ref id="B62-biomolecules-14-00969">
        <label>62.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Fahrmann</surname><given-names>J.F.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Y.-J.</given-names></name>
<name><surname>Tripathi</surname><given-names>S.C.</given-names></name>
<name><surname>Yue</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Lifshitz</surname><given-names>V.</given-names></name>
<name><surname>Song</surname><given-names>J.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
</person-group><article-title>JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance</article-title><source>Cell Metab.</source><year>2018</year><volume>27</volume><fpage>136</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.11.001</pub-id><pub-id pub-id-type="pmid">29249690</pub-id>
</element-citation>
      </ref>
      <ref id="B63-biomolecules-14-00969">
        <label>63.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peruzzi</surname><given-names>B.</given-names></name>
<name><surname>Bottaro</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Targeting the c-Met signaling pathway in cancer</article-title><source>Clin. Cancer Res.</source><year>2006</year><volume>12</volume><fpage>3657</fpage><lpage>3660</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0818</pub-id><pub-id pub-id-type="pmid">16778093</pub-id>
</element-citation>
      </ref>
      <ref id="B64-biomolecules-14-00969">
        <label>64.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Comoglio</surname><given-names>P.M.</given-names></name>
<name><surname>Trusolino</surname><given-names>L.</given-names></name>
</person-group><article-title>Series Introduction: Invasive growth: From development to metastasis</article-title><source>J. Clin. Investig.</source><year>2002</year><volume>109</volume><fpage>857</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1172/JCI0215392</pub-id><pub-id pub-id-type="pmid">11927611</pub-id>
</element-citation>
      </ref>
      <ref id="B65-biomolecules-14-00969">
        <label>65.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aumailley</surname><given-names>M.</given-names></name>
</person-group><article-title>The laminin family</article-title><source>Cell Adh. Migr.</source><year>2013</year><volume>7</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.4161/cam.22826</pub-id><pub-id pub-id-type="pmid">23263632</pub-id>
</element-citation>
      </ref>
      <ref id="B66-biomolecules-14-00969">
        <label>66.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Bi</surname><given-names>G.</given-names></name>
<name><surname>Liang</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Lu</surname><given-names>T.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Sui</surname><given-names>Q.</given-names></name>
</person-group><article-title>Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma</article-title><source>Int. J. Biol. Sci.</source><year>2020</year><volume>16</volume><elocation-id>2205</elocation-id><pub-id pub-id-type="doi">10.7150/ijbs.42080</pub-id><pub-id pub-id-type="pmid">32549766</pub-id>
</element-citation>
      </ref>
      <ref id="B67-biomolecules-14-00969">
        <label>67.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ran</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Ran</surname><given-names>W.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Hong</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
</person-group><article-title>LAMB1 is related to the T stage and indicates poor prognosis in gastric cancer</article-title><source>Technol. Cancer Res. Treat.</source><year>2021</year><volume>20</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1177/15330338211004944</pub-id><pub-id pub-id-type="pmid">33784890</pub-id>
</element-citation>
      </ref>
      <ref id="B68-biomolecules-14-00969">
        <label>68.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>W.-J.</given-names></name>
<name><surname>Kang</surname><given-names>H.-G.</given-names></name>
<name><surname>Jang</surname><given-names>J.-H.</given-names></name>
<name><surname>Choi</surname><given-names>I.J.</given-names></name>
<name><surname>Chun</surname><given-names>K.-H.</given-names></name>
<name><surname>Kim</surname><given-names>S.-J.</given-names></name>
</person-group><article-title>Upregulation of LAMB1 via ERK/c-Jun axis promotes gastric cancer growth and motility</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>626</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22020626</pub-id><pub-id pub-id-type="pmid">33435161</pub-id>
</element-citation>
      </ref>
      <ref id="B69-biomolecules-14-00969">
        <label>69.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakaguchi</surname><given-names>T.</given-names></name>
<name><surname>Yoshino</surname><given-names>H.</given-names></name>
<name><surname>Yonemori</surname><given-names>M.</given-names></name>
<name><surname>Miyamoto</surname><given-names>K.</given-names></name>
<name><surname>Sugita</surname><given-names>S.</given-names></name>
<name><surname>Matsushita</surname><given-names>R.</given-names></name>
<name><surname>Itesako</surname><given-names>T.</given-names></name>
<name><surname>Tatarano</surname><given-names>S.</given-names></name>
<name><surname>Nakagawa</surname><given-names>M.</given-names></name>
<name><surname>Enokida</surname><given-names>H.</given-names></name>
</person-group><article-title>Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer</article-title><source>Br. J. Cancer</source><year>2017</year><volume>116</volume><fpage>1077</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.43</pub-id><pub-id pub-id-type="pmid">28324890</pub-id>
</element-citation>
      </ref>
      <ref id="B70-biomolecules-14-00969">
        <label>70.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stoeck</surname><given-names>A.</given-names></name>
<name><surname>Lejnine</surname><given-names>S.</given-names></name>
<name><surname>Truong</surname><given-names>A.</given-names></name>
<name><surname>Pan</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zang</surname><given-names>C.</given-names></name>
<name><surname>Yuan</surname><given-names>J.</given-names></name>
<name><surname>Ware</surname><given-names>C.</given-names></name>
<name><surname>MacLean</surname><given-names>J.</given-names></name>
<name><surname>Garrett-Engele</surname><given-names>P.W.</given-names></name>
</person-group><article-title>Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma</article-title><source>Cancer Discov.</source><year>2014</year><volume>4</volume><fpage>1154</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0830</pub-id><pub-id pub-id-type="pmid">25104330</pub-id>
</element-citation>
      </ref>
      <ref id="B71-biomolecules-14-00969">
        <label>71.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>N.J.</given-names></name>
<name><surname>Sanborn</surname><given-names>Z.</given-names></name>
<name><surname>Arnett</surname><given-names>K.L.</given-names></name>
<name><surname>Bayston</surname><given-names>L.J.</given-names></name>
<name><surname>Liao</surname><given-names>W.</given-names></name>
<name><surname>Proby</surname><given-names>C.M.</given-names></name>
<name><surname>Leigh</surname><given-names>I.M.</given-names></name>
<name><surname>Collisson</surname><given-names>E.A.</given-names></name>
<name><surname>Gordon</surname><given-names>P.B.</given-names></name>
<name><surname>Jakkula</surname><given-names>L.</given-names></name>
</person-group><article-title>Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>17761</fpage><lpage>17766</lpage><pub-id pub-id-type="doi">10.1073/pnas.1114669108</pub-id><pub-id pub-id-type="pmid">22006338</pub-id>
</element-citation>
      </ref>
      <ref id="B72-biomolecules-14-00969">
        <label>72.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pancewicz</surname><given-names>J.</given-names></name>
<name><surname>Taylor</surname><given-names>J.M.</given-names></name>
<name><surname>Datta</surname><given-names>A.</given-names></name>
<name><surname>Baydoun</surname><given-names>H.H.</given-names></name>
<name><surname>Waldmann</surname><given-names>T.A.</given-names></name>
<name><surname>Hermine</surname><given-names>O.</given-names></name>
<name><surname>Nicot</surname><given-names>C.</given-names></name>
</person-group><article-title>Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1–associated adult T-cell leukemia</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>16619</fpage><lpage>16624</lpage><pub-id pub-id-type="doi">10.1073/pnas.1010722107</pub-id><pub-id pub-id-type="pmid">20823234</pub-id>
</element-citation>
      </ref>
      <ref id="B73-biomolecules-14-00969">
        <label>73.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuhnert</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Coetzee</surname><given-names>S.</given-names></name>
<name><surname>Thambi</surname><given-names>N.</given-names></name>
<name><surname>Hickey</surname><given-names>C.</given-names></name>
<name><surname>Shan</surname><given-names>J.</given-names></name>
<name><surname>Kovalenko</surname><given-names>P.</given-names></name>
<name><surname>Noguera-Troise</surname><given-names>I.</given-names></name>
<name><surname>Smith</surname><given-names>E.</given-names></name>
<name><surname>Fairhurst</surname><given-names>J.</given-names></name>
</person-group><article-title>Dll4 blockade in stromal cells mediates antitumor effects in preclinical models of ovarian cancer</article-title><source>Cancer Res.</source><year>2015</year><volume>75</volume><fpage>4086</fpage><lpage>4096</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3773</pub-id><pub-id pub-id-type="pmid">26377940</pub-id>
</element-citation>
      </ref>
      <ref id="B74-biomolecules-14-00969">
        <label>74.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Ye</surname><given-names>X.</given-names></name>
<name><surname>Fan</surname><given-names>F.</given-names></name>
<name><surname>Xia</surname><given-names>L.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>R.</given-names></name>
<name><surname>Bellister</surname><given-names>S.</given-names></name>
<name><surname>Tozzi</surname><given-names>F.</given-names></name>
<name><surname>Sceusi</surname><given-names>E.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Tachibana</surname><given-names>I.</given-names></name>
</person-group><article-title>Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1</article-title><source>Cancer Cell</source><year>2013</year><volume>23</volume><fpage>171</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.12.021</pub-id><pub-id pub-id-type="pmid">23375636</pub-id>
</element-citation>
      </ref>
      <ref id="B75-biomolecules-14-00969">
        <label>75.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>F.</given-names></name>
<name><surname>Ding</surname><given-names>Y.J.</given-names></name>
<name><surname>Dai</surname><given-names>M.Y.</given-names></name>
<name><surname>Yi</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Tao</surname><given-names>Z.Z.</given-names></name>
<name><surname>Chen</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Notch 2 signaling contributes to cell growth, anti-apoptosis and metastasis in laryngeal squamous cell carcinoma</article-title><source>Mol. Med. Rep.</source><year>2016</year><volume>14</volume><fpage>3517</fpage><lpage>3524</lpage><pub-id pub-id-type="doi">10.3892/mmr.2016.5688</pub-id><pub-id pub-id-type="pmid">27572051</pub-id>
</element-citation>
      </ref>
      <ref id="B76-biomolecules-14-00969">
        <label>76.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beverly</surname><given-names>L.J.</given-names></name>
<name><surname>Felsher</surname><given-names>D.W.</given-names></name>
<name><surname>Capobianco</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Suppression of p53 by Notch in lymphomagenesis: Implications for initiation and regression</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>7159</fpage><lpage>7168</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1664</pub-id><pub-id pub-id-type="pmid">16103066</pub-id>
</element-citation>
      </ref>
      <ref id="B77-biomolecules-14-00969">
        <label>77.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dotto</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Crosstalk of Notch with p53 and p63 in cancer growth control</article-title><source>Nat. Rev. Cancer</source><year>2009</year><volume>9</volume><fpage>587</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1038/nrc2675</pub-id><pub-id pub-id-type="pmid">19609265</pub-id>
</element-citation>
      </ref>
      <ref id="B78-biomolecules-14-00969">
        <label>78.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Capaccione</surname><given-names>K.M.</given-names></name>
<name><surname>Pine</surname><given-names>S.R.</given-names></name>
</person-group><article-title>The Notch signaling pathway as a mediator of tumor survival</article-title><source>Carcinogenesis</source><year>2013</year><volume>34</volume><fpage>1420</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgt127</pub-id><pub-id pub-id-type="pmid">23585460</pub-id>
</element-citation>
      </ref>
      <ref id="B79-biomolecules-14-00969">
        <label>79.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qu</surname><given-names>J.</given-names></name>
<name><surname>Song</surname><given-names>M.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>X.-Y.</given-names></name>
<name><surname>Hu</surname><given-names>X.-M.</given-names></name>
<name><surname>Gan</surname><given-names>R.-H.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Lin</surname><given-names>L.-S.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Lin</surname><given-names>X.</given-names></name>
</person-group><article-title>Notch2 signaling contributes to cell growth, invasion, and migration in salivary adenoid cystic carcinoma</article-title><source>Mol. Cell. Biochem.</source><year>2016</year><volume>411</volume><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1007/s11010-015-2575-z</pub-id><pub-id pub-id-type="pmid">26427670</pub-id>
</element-citation>
      </ref>
      <ref id="B80-biomolecules-14-00969">
        <label>80.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>H.-M.</given-names></name>
<name><surname>Jiang</surname><given-names>X.-S.</given-names></name>
<name><surname>Li</surname><given-names>H.-Z.</given-names></name>
<name><surname>Qian</surname><given-names>L.-X.</given-names></name>
<name><surname>Du</surname><given-names>M.-Y.</given-names></name>
<name><surname>Lu</surname><given-names>Z.-W.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Tian</surname><given-names>X.-K.</given-names></name>
<name><surname>Fei</surname><given-names>Q.</given-names></name>
<name><surname>He</surname><given-names>X.</given-names></name>
</person-group><article-title>miR-184 inhibits tumor invasion, migration and metastasis in nasopharyngeal carcinoma by targeting Notch2</article-title><source>Cell. Physiol. Biochem.</source><year>2018</year><volume>49</volume><fpage>1564</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1159/000493459</pub-id><pub-id pub-id-type="pmid">30223264</pub-id>
</element-citation>
      </ref>
      <ref id="B81-biomolecules-14-00969">
        <label>81.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<name><surname>Setoguchi</surname><given-names>T.</given-names></name>
<name><surname>Hirotsu</surname><given-names>M.</given-names></name>
<name><surname>Gao</surname><given-names>H.</given-names></name>
<name><surname>Sasaki</surname><given-names>H.</given-names></name>
<name><surname>Matsunoshita</surname><given-names>Y.</given-names></name>
<name><surname>Komiya</surname><given-names>S.</given-names></name>
</person-group><article-title>Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation</article-title><source>Br. J. Cancer</source><year>2009</year><volume>100</volume><fpage>1957</fpage><lpage>1965</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605060</pub-id><pub-id pub-id-type="pmid">19455146</pub-id>
</element-citation>
      </ref>
      <ref id="B82-biomolecules-14-00969">
        <label>82.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>W.-X.</given-names></name>
<name><surname>Wu</surname><given-names>Z.-M.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Lin</surname><given-names>J.-H.</given-names></name>
</person-group><article-title>Notch2 and Notch3 suppress the proliferation and mediate invasion of trophoblast cell lines</article-title><source>Biol. Open</source><year>2017</year><volume>6</volume><fpage>1123</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1242/bio.025767</pub-id><pub-id pub-id-type="pmid">28606936</pub-id>
</element-citation>
      </ref>
      <ref id="B83-biomolecules-14-00969">
        <label>83.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Craene</surname><given-names>B.D.</given-names></name>
<name><surname>Berx</surname><given-names>G.</given-names></name>
</person-group><article-title>Regulatory networks defining EMT during cancer initiation and progression</article-title><source>Nat. Rev. Cancer</source><year>2013</year><volume>13</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nrc3447</pub-id><pub-id pub-id-type="pmid">23344542</pub-id>
</element-citation>
      </ref>
      <ref id="B84-biomolecules-14-00969">
        <label>84.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thiery</surname><given-names>J.P.</given-names></name>
<name><surname>Acloque</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>R.Y.</given-names></name>
<name><surname>Nieto</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Epithelial-mesenchymal transitions in development and disease</article-title><source>Cell</source><year>2009</year><volume>139</volume><fpage>871</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.11.007</pub-id><pub-id pub-id-type="pmid">19945376</pub-id>
</element-citation>
      </ref>
      <ref id="B85-biomolecules-14-00969">
        <label>85.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Otte</surname><given-names>J.</given-names></name>
<name><surname>Dizdar</surname><given-names>L.</given-names></name>
<name><surname>Behrens</surname><given-names>B.</given-names></name>
<name><surname>Goering</surname><given-names>W.</given-names></name>
<name><surname>Knoefel</surname><given-names>W.T.</given-names></name>
<name><surname>Wruck</surname><given-names>W.</given-names></name>
<name><surname>Stoecklein</surname><given-names>N.H.</given-names></name>
<name><surname>Adjaye</surname><given-names>J.</given-names></name>
</person-group><article-title>FGF signalling in the self-renewal of colon cancer organoids</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>17365</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-53907-7</pub-id><pub-id pub-id-type="pmid">31758153</pub-id>
</element-citation>
      </ref>
      <ref id="B86-biomolecules-14-00969">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ye</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>B.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Stewart</surname><given-names>J.P.</given-names></name>
<name><surname>Johnson</surname><given-names>S.K.</given-names></name>
<name><surname>Barlogie</surname><given-names>B.</given-names></name>
<name><surname>Zangari</surname><given-names>M.</given-names></name>
<name><surname>Tricot</surname><given-names>G.</given-names></name>
</person-group>
          <article-title>N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma</article-title>
          <source>Blood</source>
          <year>2021</year>
          <volume>138</volume>
          <fpage>1572</fpage>
          <pub-id pub-id-type="doi">10.1182/blood-2021-148624</pub-id>
        </element-citation>
      </ref>
      <ref id="B87-biomolecules-14-00969">
        <label>87.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciołczyk-Wierzbicka</surname><given-names>D.</given-names></name>
<name><surname>Laidler</surname><given-names>P.</given-names></name>
</person-group><article-title>The inhibition of invasion of human melanoma cells through N-cadherin knock-down</article-title><source>Med. Oncol.</source><year>2018</year><volume>35</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1007/s12032-018-1104-9</pub-id><pub-id pub-id-type="pmid">29492694</pub-id>
</element-citation>
      </ref>
      <ref id="B88-biomolecules-14-00969">
        <label>88.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>He</surname><given-names>W.</given-names></name>
<name><surname>Lin</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Fan</surname><given-names>Q.-X.</given-names></name>
</person-group><article-title>N-cadherin knock-down decreases invasiveness of esophageal squamous cell carcinoma in vitro</article-title><source>World J. Gastroenterol. WJG</source><year>2009</year><volume>15</volume><fpage>697</fpage><pub-id pub-id-type="doi">10.3748/wjg.15.697</pub-id><pub-id pub-id-type="pmid">19222093</pub-id>
</element-citation>
      </ref>
      <ref id="B89-biomolecules-14-00969">
        <label>89.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joshi</surname><given-names>V.</given-names></name>
<name><surname>Lakhani</surname><given-names>S.R.</given-names></name>
<name><surname>McCart Reed</surname><given-names>A.E.</given-names></name>
</person-group><article-title>NDRG1 in Cancer: A Suppressor, Promoter, or Both?</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>5739</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14235739</pub-id><pub-id pub-id-type="pmid">36497221</pub-id>
</element-citation>
      </ref>
      <ref id="B90-biomolecules-14-00969">
        <label>90.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guan</surname><given-names>R.J.</given-names></name>
<name><surname>Ford</surname><given-names>H.L.</given-names></name>
<name><surname>Fu</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Shaw</surname><given-names>L.M.</given-names></name>
<name><surname>Pardee</surname><given-names>A.B.</given-names></name>
</person-group><article-title><italic toggle="yes">Drg-1</italic> as a differentiation-related, putative metastatic suppressor gene in human colon cancer</article-title><source>Cancer Res.</source><year>2000</year><volume>60</volume><fpage>749</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">10676663</pub-id>
</element-citation>
      </ref>
      <ref id="B91-biomolecules-14-00969">
        <label>91.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maruyama</surname><given-names>Y.</given-names></name>
<name><surname>Ono</surname><given-names>M.</given-names></name>
<name><surname>Kawahara</surname><given-names>A.</given-names></name>
<name><surname>Yokoyama</surname><given-names>T.</given-names></name>
<name><surname>Basaki</surname><given-names>Y.</given-names></name>
<name><surname>Kage</surname><given-names>M.</given-names></name>
<name><surname>Aoyagi</surname><given-names>S.</given-names></name>
<name><surname>Kinoshita</surname><given-names>H.</given-names></name>
<name><surname>Kuwano</surname><given-names>M.</given-names></name>
</person-group><article-title>Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>6233</fpage><lpage>6242</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0183</pub-id><pub-id pub-id-type="pmid">16778198</pub-id>
</element-citation>
      </ref>
      <ref id="B92-biomolecules-14-00969">
        <label>92.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bandyopadhyay</surname><given-names>S.</given-names></name>
<name><surname>Pai</surname><given-names>S.K.</given-names></name>
<name><surname>Hirota</surname><given-names>S.</given-names></name>
<name><surname>Hosobe</surname><given-names>S.</given-names></name>
<name><surname>Takano</surname><given-names>Y.</given-names></name>
<name><surname>Saito</surname><given-names>K.</given-names></name>
<name><surname>Piquemal</surname><given-names>D.</given-names></name>
<name><surname>Commes</surname><given-names>T.</given-names></name>
<name><surname>Watabe</surname><given-names>M.</given-names></name>
<name><surname>Gross</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>5675</fpage><lpage>5681</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207734</pub-id><pub-id pub-id-type="pmid">15184886</pub-id>
</element-citation>
      </ref>
      <ref id="B93-biomolecules-14-00969">
        <label>93.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akiba</surname><given-names>J.</given-names></name>
<name><surname>Ogasawara</surname><given-names>S.</given-names></name>
<name><surname>Kawahara</surname><given-names>A.</given-names></name>
<name><surname>Nishida</surname><given-names>N.</given-names></name>
<name><surname>Sanada</surname><given-names>S.</given-names></name>
<name><surname>Moriya</surname><given-names>F.</given-names></name>
<name><surname>Kuwano</surname><given-names>M.</given-names></name>
<name><surname>Nakashima</surname><given-names>O.</given-names></name>
<name><surname>Yano</surname><given-names>H.</given-names></name>
</person-group><article-title>N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma</article-title><source>Oncol. Rep.</source><year>2008</year><volume>20</volume><fpage>1329</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.3892/or_00000148</pub-id><pub-id pub-id-type="pmid">19020710</pub-id>
</element-citation>
      </ref>
      <ref id="B94-biomolecules-14-00969">
        <label>94.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ai</surname><given-names>R.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Wei</surname><given-names>W.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Hendricks</surname><given-names>D.T.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
</person-group><article-title>NDRG1 overexpression promotes the progression of esophageal squamous cell carcinoma through modulating Wnt signaling pathway</article-title><source>Cancer Biol. Ther.</source><year>2016</year><volume>17</volume><fpage>943</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1080/15384047.2016.1210734</pub-id><pub-id pub-id-type="pmid">27414086</pub-id>
</element-citation>
      </ref>
      <ref id="B95-biomolecules-14-00969">
        <label>95.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ureshino</surname><given-names>H.</given-names></name>
<name><surname>Murakami</surname><given-names>Y.</given-names></name>
<name><surname>Watari</surname><given-names>K.</given-names></name>
<name><surname>Izumi</surname><given-names>H.</given-names></name>
<name><surname>Kawahara</surname><given-names>A.</given-names></name>
<name><surname>Kage</surname><given-names>M.</given-names></name>
<name><surname>Arao</surname><given-names>T.</given-names></name>
<name><surname>Nishio</surname><given-names>K.</given-names></name>
<name><surname>Yanagihara</surname><given-names>K.</given-names></name>
<name><surname>Kinoshita</surname><given-names>H.</given-names></name>
</person-group><article-title>N-myc downstream regulated gene 1 (NDRG1) promotes metastasis of human scirrhous gastric cancer cells through epithelial mesenchymal transition</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e41312</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0041312</pub-id><pub-id pub-id-type="pmid">22844455</pub-id>
</element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig position="float" id="biomolecules-14-00969-f001">
      <label>Figure 1</label>
      <caption>
        <p>Phenotypic study of drug-resistant CCA cell lines. Drug sensitivity assay of KKU-213FR (<bold>a</bold>) and KKU-213GR (<bold>b</bold>). (<bold>c</bold>) Cell migration assay. (<bold>d</bold>) Cell invasion assay: magnification 100×; scale bar, 100 μm. The data are presented as mean ± SD from three replicates. Significant differences between treated versus untreated controls or parental versus drug-resistant cells are indicated by * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, and *** <italic toggle="yes">p</italic> &lt; 0.001.</p>
      </caption>
      <graphic xlink:href="biomolecules-14-00969-g001" position="float"/>
    </fig>
    <fig position="float" id="biomolecules-14-00969-f002">
      <label>Figure 2</label>
      <caption>
        <p>Proteomics analysis of KKU-213A, KKU-213FR, and KKU-213GR cell lines. (<bold>a</bold>) Proteomics analysis workflow. (<bold>b</bold>) Partial least squares-discriminant analysis (PLS-DA) of all identified proteins. Venn diagram of upregulated proteins (<bold>c</bold>) and down-regulated proteins (<bold>d</bold>) in KKU-213FR and KKU-213GR compared to KKU-213A. (<bold>e</bold>) Heatmap with group averages of upregulated (red frame) and down-regulated (green frame) proteins shared among KKU-213A, KKU-213FR, and KKU-213GR.</p>
      </caption>
      <graphic xlink:href="biomolecules-14-00969-g002" position="float"/>
    </fig>
    <fig position="float" id="biomolecules-14-00969-f003">
      <label>Figure 3</label>
      <caption>
        <p>Gene Ontology analysis of upregulated proteins shared in KKU-213FR and KKU-213GR. The analysis represents the proteins hits and their respective percentages. Analysis based on molecular functions (<bold>a</bold>), biological processes (<bold>b</bold>), and protein classes (<bold>c</bold>).</p>
      </caption>
      <graphic xlink:href="biomolecules-14-00969-g003" position="float"/>
    </fig>
    <fig position="float" id="biomolecules-14-00969-f004">
      <label>Figure 4</label>
      <caption>
        <p>Identification of significant genes in CCA. (<bold>a</bold>) The Venn diagram represents 80 upregulated proteins from the proteomic analysis and 25 upregulated genes in CCA tissue compared to normal tissue. (<bold>b</bold>) Heatmap analysis displaying the expression of 25 overlapping genes that were significantly upregulated in CCA patients’ tissues based on TCGA data (left) and proteomics data (right). (<bold>c</bold>) PPI analysis of the 25 upregulated genes via STRING. (<bold>d</bold>) Box plot showing the mRNA expression of six selected genes (a focused network) in CCA patients’ tissues (red box) vs. normal tissues (grey box) based on TCGA data. Significant differences between groups are indicated by * <italic toggle="yes">p</italic> &lt; 0.05. (<bold>e</bold>) The mRNA expression of six selected genes verified by RT-qPCR in KKU-213A, KKU-213FR, and KKU-213GR. Significant differences between the KKU-213A and KKU-213FR groups, as well as between the KKU-213A and KKU-213GR groups, are indicated by *** <italic toggle="yes">p</italic> &lt; 0.001.</p>
      </caption>
      <graphic xlink:href="biomolecules-14-00969-g004" position="float"/>
    </fig>
    <fig position="float" id="biomolecules-14-00969-f005">
      <label>Figure 5</label>
      <caption>
        <p>Survival analyses of six selected genes in GI tract cancer patients. The overall survival map (<bold>a</bold>) and disease-free survival map (<bold>b</bold>) are displayed. Red shading indicates poor prognosis, and blue shading indicates good prognostic potential for each gene. The box with a prominent border represents statistical significance. Kaplan–Meier plots are used to represent overall survival (<bold>c</bold>) and disease-free survival (<bold>d</bold>).</p>
      </caption>
      <graphic xlink:href="biomolecules-14-00969-g005" position="float"/>
    </fig>
    <fig position="float" id="biomolecules-14-00969-f006">
      <label>Figure 6</label>
      <caption>
        <p>The correlation analysis of six focused genes in GI tract cancers includes. (<bold>a</bold>) Scatter plots depicting the expression correlation between gene pairs in GI tract cancers. (<bold>b</bold>) Summary of the significant correlations among gene pairs in GI tract cancers. Yellow color indicates a positive correlation, blue color indicates a negative correlation, and grey color indicates no significant correlation between genes. Significant correlations between gene pairs are indicated by *** <italic toggle="yes">p</italic> &lt; 0.001, while <italic toggle="yes">NS</italic> denotes non-significance.</p>
      </caption>
      <graphic xlink:href="biomolecules-14-00969-g006" position="float"/>
    </fig>
    <fig position="float" id="biomolecules-14-00969-f007">
      <label>Figure 7</label>
      <caption>
        <p>Phenotypic study after knockdown of six selected genes in KKU-213FR and KKU-213GR cells. (<bold>a</bold>) mRNA expression after siRNA transfection. (<bold>b</bold>) Cell migration assay. (<bold>c</bold>) Cell invasion assay. (<bold>d</bold>) Drug sensitivity assay. Data are presented as mean ± SD from three replicates. Significant differences between siRNA-transfected cells and siNC-transfected controls are indicated by * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, and *** <italic toggle="yes">p</italic> &lt; 0.001, magnification 100×; scale bar, 100 μm.</p>
      </caption>
      <graphic xlink:href="biomolecules-14-00969-g007" position="float"/>
    </fig>
    <fig position="float" id="biomolecules-14-00969-f008">
      <label>Figure 8</label>
      <caption>
        <p>Hypothetical role of six selected genes in CCA progression. A schematic illustration delineating the putative role of the selected genes, elucidating their hypothesized involvement in driving drug resistance and promoting the progression of CCA cells. This figure was constructed using BioRender (2023).</p>
      </caption>
      <graphic xlink:href="biomolecules-14-00969-g008" position="float"/>
    </fig>
    <table-wrap position="float" id="biomolecules-14-00969-t001">
      <object-id pub-id-type="pii">biomolecules-14-00969-t001_Table 1</object-id>
      <label>Table 1</label>
      <caption>
        <p>Lists of gene-specific primers for RT-qPCR.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th>
            <th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Sequence (5′ to 3′)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">ACTB</italic>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGATTCCTATGTGGGCGACG</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rev:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TTGTAGAAGGTGTGGTGCCAG</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">MET</italic>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CGCACAAAGCAAGCCAGATT</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rev:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGTGCTCATGATTGGGTCCG</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">LAMB1</italic>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGCAATCTGAAAATGGTGTGGA</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rev:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACGAGGCCTCACAGTCATAG</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">ITGA3</italic>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGGACAGTGATGGGTGAGTC</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rev:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GTAGGGCCACTCCAGACCTA</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">NOTCH2</italic>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGGTGTCAGAATGGAGGGGT</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rev:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCCGTTGACACATACACAGC</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">CDH2</italic>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGCAAGACTGGATTTCCTGAAGA</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rev:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGCTTCTCACGGCATACACC</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">NDRG1</italic>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATTGGCATGGGAACAGGAGC</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rev:</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CATCCTGAGATCTTGGAGGCG</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="biomolecules-14-00969-t002">
      <object-id pub-id-type="pii">biomolecules-14-00969-t002_Table 2</object-id>
      <label>Table 2</label>
      <caption>
        <p>List of siRNAs for gene knockdown.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">siRNA</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Gene</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">siRNA Sequence (5′ to 3′)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siMET</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MET</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGACCGGUUCAUCAACUUCTT</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siLAMB1</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LAMB1</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAUGUAACUGCAAUGAACATT</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siITGA3</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ITGA3</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGAAAGGAAACAGCUACAUGATT</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siNOTCH2</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NOTCH2</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GAAUUGUCAGACAGUAUUGTT</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siCDH2</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDH2</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UGACAACAGACCUGAGUUCTT</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siNDRG1</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NDRG1</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GACCACUCUCCUCAAGAUGTT</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siNC</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UUCUCCGAACGUGUCACGUTT</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
